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Summary 
SUMMARY 
 
Flaviviruses form a genus in the family of Flaviviridae and comprise a number of 
important human pathogens, such as yellow fever, dengue, West Nile, Japanese 
encephalitis, and tick-borne encephalitis viruses. These viruses have a world wide 
distribution and the potential to emerge in new geographic areas and thus are a 
major concern for public health. Structurally, flaviviruses are extremely well 
characterized by a combination of cryo-electron microscopy and X-ray 
crystallography of the major envelope protein E. Infection or immunization with 
flaviviruses induces a protective antibody response which is mainly directed to E. 
Epitopes involved in virus neutralization were identified in all domains of E, having 
different neutralizing potential. Broadly cross-reactive antibodies, directed to the so-
called fusion loop in E, appear to have relatively low neutralizing activity but comprise 
a major fraction in human post-infection sera. In contrast, antibodies to domain III 
(DIII) of E have the highest neutralizing potency and represent a significant fraction in 
murine but not in human post-infection sera. 
The major objective of this thesis was to investigate the influence of the physical 
organisation of flavivirus immunogens on the fine-specificity, immunodominance and 
functional quality of antibody responses. It was a further objective to specifically 
design prime-boost immunization regimens that focus the antibody response to the 
highly neutralizing sites of DIII in E. For these purposes, mouse immunization studies 
were conducted using whole inactivated purified virus (displaying a closed shell of 
tightly packed E proteins), a monomeric soluble form of E and the isolated DIII of 
West Nile virus as immunogens.The major findings of this work have been published 
in the Journal of Virology (Part I of the thesis). 
Analyses of the post-immunization sera revealed that virion and sE induced 
significantly different proportions of DIII-reactive antibodies which in both cases 
dominated the neutralizing response. However, the functional quality of the DIII-
reactive antibodies induced by virion immunization was 4 times higher than that after 
sE immunization, and those induced by the isolated DIII had an even 15-fold lower 
neutralizing quality compared to the virion. They also failed to completely neutralize 
the virus and only 50% of these antibodies were able to bind to viral particles. These 
results suggest that the E protein in its tightly packed arrangement on the surface of 
whole virions is an extremely efficient form presenting those DIII epitopes that are 
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primary targets for neutralization. In contrast, soluble antigens focus the antibody 
response not as efficiently to the determinants critical for neutralization but rather 
induce antibodies to sites not exposed on the viral surface and thus contribute less to 
neutralization. Further analyses revealed that the avidity of the antibodies for the 
virus were highest after virion- followed by sE- and DIII-immunization, representing a 
possible additional contributing factor to the distinct neutralizing quality of the DIII-
reactive antibodies. 
Sequential prime-boost immunization regimens using DIII either for priming or for 
boosting demonstrated that DIII is an excellent booster antigen which restimulates 
the DIII specific neutralizing response after priming with virion or sE more strongly 
than the homologous antigen. Surprisingly, priming with DIII followed by sE or virion 
immunization resulted in a dampening of the antibody response compared to mice 
without DIII priming. 
The data presented provide novel insights into the fine-specificity of the antibody 
response induced by virus as compared to recombinant subunit vaccines and 
demonstrated the potential of using an individual protein domain (DIII) for boosting 
the most strongly virus neutralizing antibodies. These findings have implications for 
the specific design of future vaccines and vaccination regimens. 
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Zusammenfassung 
ZUSAMMENFASSUNG 
 
Flaviviren bilden ein Genus in der Familie Flaviviridae und umfassen eine Reihe 
von wichtigen Krankheitserregern wie Gelbfieber, Dengue, Japanische Enzephalitis, 
Frühsommer-Meningoenzephalitis oder West Nil Viren. Aufgrund ihrer weltweiten 
Verbreitung und dem möglichen Auftreten in neuen geographischen Regionen 
repräsentieren Flaviviren Krankheitserreger mit hoher epidemiologischer und 
klinischer Relevanz. Die Struktur von Flaviviren wurde mit Hilfe von Kryo-
Elektronenmikroskopie und Kristallographie des viralen Hauptoberflächenproteins E 
aufgeklärt. Die nach Infektion oder Immunisierung mit Flavivirus induzierten 
Antikörper sind protektiv und zum größten Teil gegen E gerichtet. Epitope 
neutralisierender Antikörper wurden in allen Domänen des E Proteins identifiziert. 
Breit Flavivirus kreuzreaktive Antikörper, welche an das Fusionspeptid in E binden, 
haben zwar meist relativ geringe neutralisierende Aktivität, repräsentieren aber 
generell einen signifikant hohen Anteil in humanen Post-Infektionsseren. Domäne III 
(DIII)-spezifische Antikörper haben die stärkste neutralisierende Aktivität und bilden 
in Mäusen einen bedeutenden Anteil an der E Protein spezifischen 
Antikörperantwort. Im Gegensatz dazu, dominiert beim Menschen die 
Antikörperantwort gegen das Fusionspeptid. 
Das Hauptziel dieser Dissertation bestand darin zu erforschen, ob der strukturelle 
Kontext des Immunogens die Feinspezifität, Immundominanz und funktionelle 
Qualität von Antikörperantworten beeinflusst. Weiters wurde untersucht, ob es 
möglich ist, mit sequentiellen Immunisierungen, unter Verwendung der isolierten DIII, 
die Antikörperantwort auf Epitope stark neutralisierender Antikörper in DIII zu 
fokussieren. Aus diesem Grund wurde eine Immunisierungsstudie im West Nil Virus 
System durchgeführt, bei der Mäuse mit Formalin inaktiviertem, gereinigtem Virus 
(umhüllt von einem kompakten Mantel aus dicht gepackten E Proteinen), dem 
löslichen E Protein (Monomer) und löslicher isolierter DIII, immunisiert wurden. Die 
Hauptergebnisse dieser Arbeit wurden im Journal of Virology veröffentlicht (siehe 
Part I der Dissertation). 
Die Analyse der Maus-Immunseren zeigte, dass sE einen signifikant höheren 
Anteil an DIII spezifischen Antikörpern induziert als das Virus, wobei diese in beiden 
Fällen den Großteil der neutralisierenden Antikörper ausmachten. Die spezifische 
neutralisierende Qualität der DIII Antikörper war nach Immunisierung mit Virus jedoch 
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4-fach höher. Die isolierte DIII induzierte nur eine vergleichbar geringe 
neutralisierende Antwort. Die spezifische neutralisierende Qualität dieser Antikörper 
war, verglichen mit Virus, zumindest 15-fach geringer, und 50% dieser Antikörper 
konnten in Absorptionsexperimenten nicht an das Viruspartikel binden. Diese Daten 
deuten darauf hin, dass das E Protein in seiner dicht gepackten Form an der 
Oberfläche viraler Partikel hauptsächlich jene Epitope in DIII präsentiert, die Ziele 
neutralisierender Antikörper sind. Im Gegensatz dazu präsentieren lösliche Antigene 
Epitope, die an der Oberfläche des viralen Partikels nicht zugänglich sind und somit 
teilweise Antikörper induzieren die nicht oder weniger zur Neutralisation von 
infektiösem Virus beitragen. 
In sequentiellen Immunisierungen mit DIII zeigte sich, dass durch Verabreichung 
von DIII nach Vorimmunisierung mit Virus oder sE die neutralisierende Antwort, im 
Vergleich zur Immunisierung mit den homologen Antigenen (sE oder Virus), deutlich 
gesteigert werden konnte. Wurde DIII jedoch als Grundimmunisierung vor Virus oder 
sE administriert, wurde eine Reduktion der Antikörperantwort, im Vergleich zu 
Mäusen ohne Vorimmunisierung, beobachtet. 
Diese Arbeit liefert neue Erkenntnisse über die Feinspezifität der 
Antikörperantwort in Mäusen nach Immunisierung mit inaktiviertem Virus und 
rekombinanten löslichen Antigenen und eröffnet die Möglichkeit mit Hilfe von 
individuellen, isolierten Domänen die neutralisierende Antwort gegen das Virus zu 
steigern. Damit können die vorgelegten Ergebnisse zur Entwicklung neuer 
Immunisierungsstrategien beitragen. 
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1. Introduction 
 
1.1 Flaviviruses – taxonomy and distribution 
 
Flaviviruses form a genus in the family of Flaviviridae, consisting of more than 70 
different viruses (25). According to their antigenic relationship, flaviviruses are 
grouped into so-called serocomplexes (Fig. 1.1) (8). Important human pathogenic 
representatives are dengue (DEN), Yellow fever (YF), West Nile (WN), Japanese 
encephalitits (JE) and tick-borne encephalitis (TBE) viruses (Fig. 1.1). They are 
distributed world wide and represent a major concern for public health in tropical and 
subtropical regions of the Americas (DEN, WN, YF), Africa (DEN, WN, YF) and Asia 
(DEN, JE, TBE), as well as in Europe (WN, TBE). Flaviviruses are mainly transmitted 
by vectors like mosquitoes or ticks, however for some representatives like Modoc or 
Rio Bravo viruses, no vectors have been described yet. 
 
 
 
Fig 1.1 Dendrogram displaying antigenic serocomplexes of flaviviruses.  
Distance relationships of different flaviviruses are indicated by the E protein amino acid identity in %. 
The serocomplexes are shown in red for dengue, green for Japanese encephalitis, orange for Yellow 
fever and blue for the tick-borne encephalitis virus serocomplex. Figure adapted from (94). 
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1.2 West Nile virus  
 
1.2.1 Taxonomy and epidemiology 
 
West Nile virus is a mosquito-borne flavivirus in the Japanese Encephalitis virus 
serocomplex (Fig. 1.1) and represents one of the most widely distributed flaviviruses 
world-wide (31). According to nucleotide sequence analysis, West Nile viruses can 
be divided into two genetically distinct lineages (54). Lineage I viruses, emerging 
globally, are distributed in Mediterranean parts of Africa and Europe, West and 
Central Asia, the Middle East, the Americas and Australia. Lineage II viruses are 
predominantly found in sub-Saharan parts of Africa but have also been recently 
detected in Central Europe (3). 
West Nile viruses are important animal and human pathogens causing generally 
asymptomatic or mild febrile diseases but, in some cases, severe potentially fatal 
disease forms including encephalitis and meningitis. The virus was first isolated in 
1937 from a febrile patient in the West Nile district of Uganda (91). Until the 1990s, 
sporadic epidemics with few severe fatal cases were reported in Africa, Russia and 
Israel, mostly in rural populations. In the 1990s, epidemics became more frequent as 
exemplified by larger outbreaks, also in urban populations, for instance in Romania 
(1996) and Russia (1999). In summer 1999, natural human infections were reported 
for the first time in North America during an outbreak in the city of New York (55). 
Sequence studies suggested that the virus, belonging to lineage I viruses, was most 
likely introduced from Israel into the United States (29). 
Until 2004, lineage II strains were detected in sub-Saharan parts of Africa only. 
However, in 2004, a lineage II strain WN virus was detected for the first time in 
Central Europe (3) in infected animals. In addition, human infections including fatal 
cases caused by lineage II viruses were reported in Russia, Romania and recently in 
Greece in 2010 (73). 
The appearance and spread of WN virus in the Americas and the emergence of 
lineage II virus strains in Europe and Russia demonstrated the potential of West Nile 
virus to emerge in new geographical areas. 
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1.2.2 Transmission 
 
West Nile virus is maintained in nature in a mosquito-bird transmission cycle 
involving predominantly mosquitoes of the genus Culex. More than 100 different bird 
species like sparrows, crows and grackles, which serve as the virus-amplifying hosts, 
can get infected with West Nile virus. After infection, birds develop a high level of 
viremia and are either asymptomatic or develop potentially fatal disease. Mosquitoes 
can get infected by having a blood meal on birds with a sufficiently high virus titer. In 
the mosquito, the virus replicates in gut epithelium and disseminates to tissues 
including the salivary glands for further amplification. 
Humans or other mammals like horses and small rodents can also get infected 
with WN virus. They develop only moderate levels of viremia and, most likely, do not 
contribute to the transmission cycle and are therefore considered as dead end hosts. 
However, they can develop mild or severe diseases, including fatal forms. Human-to-
human transmission has been documented sporadically by blood transfusions, organ 
transplants or breast feeding from viremic donors to non-immune recipients (35). 
 
 
1.2.3 Pathogenesis 
 
1.2.3.1 Clinical manifestations in humans 
 
Seroprevalence studies in humans suggest that 80% of the West Nile virus 
infected individuals do not develop any significant disease symptoms. In clinically 
overt cases, febrile, flu-like symptoms occur within 2-14 days post-infection. The 
disease is generally self limiting, however, about 1% of the patients develop severe 
neuroinvasive forms like meningitis, encephalitis, or acute flaccid paralysis with a 
mortality rate of 10-20% (9). Immunosuppressed individuals like transplant patients, 
HIV-infected or elderly, represent groups which have an increased risk for developing 
severe disease forms. 
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1.2.3.2 Viral dissemination in humans 
 
After inoculation through mosquitoes, WN virus infects and replicates in skin 
Langerhans dendritic cells, which migrate to draining lymph nodes. The virus 
subsequently enters the blood stream via the thoracic duct or efferent lymphatic 
vessels causing a primary viremia. The virus continues to spread via the circulation 
and infects peripheral tissues like cells of the reticuloendothelial system and visceral 
organs, for instance spleen and kidney, leading to secondary viremia. West Nile virus 
is capable of crossing the blood brain barrier via the hematogenous route (20), 
retrograde axonal transport (85), or infected inflammatory cells. In the central nervous 
system apoptosis can be induced in infected neurons causing significant neuronal 
tissue damage. 
 
 
1.3 Molecular biology of flaviviruses 
 
1.3.1 Genome structure 
 
The genome of flaviviruses is a ~11kb long, single stranded, positive sense RNA 
molecule. A cap structure is located at the 5` terminus, however, there is no poly-A 
tail at the 3`terminus. The non-coding regions (NCR) at the 5`and 3` terminal regions 
are highly structured and are involved in genome cyclization, replication and 
translation (63). The genome has a single open reading frame encoding three 
structural proteins C, prM, E and seven non-structural proteins NS1, 2A, 2B, 3, 4A, 
4B, 5 (Fig. 1.2A), (60). 
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Fig. 1.2 Schematic representations of the flavivirus genome and polyprotein. 
(A) A single long open reading frame encodes all structural proteins (C, prM, E) and non-structural 
proteins (NS1, 2A, 2B, 3, 4A, 4B, 5). NC indicates the non-coding regions at both ends of the genome. 
(B) Schematic of the polyprotein, and its association with the membrane of the endoplasmic reticulum 
(ER). Cleavage sites for proteolytic processing by viral and host proteases are indicated by green 
(NS2B3 cleavage sites), white (signalase cleavage sites) and red arrows (furin cleavage site). The 
figure was adapted from the PhD Thesis, K. Orlinger: ‘Construction and Application of Bicistronic 
Flaviviruses’; University of Vienna 2007. 
 
 
1.3.2 Structure of the viral particle 
 
Flavivirus virions are small particles with a diameter of about 50 nanometres (nm). 
The single stranded positive sense RNA genome, which is about 11 kilobases (kb) 
long, is packed into a spherical capsid structure composed of the viral structural 
protein C. This nucleocapsid is enveloped by a host cell-derived lipid bilayer in which 
the viral transmembrane proteins E and prM/M are anchored (60). 
 17     
Introduction 
In the host cell, flavivirus virions are assembled as immature particles, which are 
not infectious. The surface of such fully immature particles is covered by 60 trimers of 
prM-E heterodimers, forming spiky projections from the surface (Fig. 1.3 and 1.5C). 
During the passage of the virus through the Trans-Golgi Network (TGN) of the host 
cell, pH dependent structural rearrangements of E and the proteolytic digest of the 
prM protein into ‘M’ and ‘pr’, which dissociates from the virion at neutral pH in the 
extracellular milieu (57, 109), lead to a structural reorganization of the proteins on the 
viral surface. In fully mature viral particles, which are now infectious, the E proteins 
form 90 antiparallel, energetically metastable, homodimers, which are organized in a 
herringbone-like icosahedral lattice. They are oriented parallel to the viral membrane 
forming a smooth surface (Fig. 1.3 and 1.5D). 
 
 
 
 
Fig. 1.3 Immature and mature flaviviruses.  
Schematic representation of the prM-E heterodimers and E homodimers, associated with the lipid 
envelope, on the surface of immature and mature viruses, respectively. Individual parts of the E 
protein are shown in red for DI, yellow for DII, blue for DIII, followed by the stem and transmembrane 
regions indicated in purple and green, respectively. The pr peptide of prM is indicated in grey and the 
extracellular part of the M protein and the transmembrane domains are shown in pink and orange, 
respectively. 
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1.3.3 The flavivirus life cycle 
 
Essential steps of the life cycle of flaviviruses are schematically shown in Fig. 1.4. 
The virus attaches to the cell via the E protein to poorly defined cellular receptors and 
is subsequently taken up by receptor-mediated endocytosis. In the endosome, acidic 
pH triggers structural rearrangements in the E protein, mediating fusion of the viral 
and endosomal membrane. The nucleocapsid is released into the cytoplasm, the 
RNA genome gets separated from the capsid protein (uncoating) and viral protein 
expression and genome replication is initiated. Flavivirus proteins are translated as a 
single polyprotein precursor from the genomic RNA and associate with the 
membrane of the endoplasmic reticulum (ER) (Fig. 1.2B). Individual proteins are 
separated co- and post-translationally by proteolytic processing of the polyprotein 
precoursor, by host signal peptidase in the lumen (signalase) and the viral serine 
protease (NS2B3) at the cytoplasmic side of the ER membrane (Fig. 1.2B). The 
structural proteins E and prM are translated into the lumen of the ER whereas the C 
protein is located at the cytoplasmic side (Fig 1.2B). Assembly of the viral particles 
takes place in the ER. The immature non-infectious particles are transported through 
the secretory pathway. In the late TGN, acidic pH triggers a conformational change in 
the prM protein rendering the furin cleavage site accessible. The prM protein is 
subsequently cleaved by furin into the “M” protein which remains associated with the 
particle via its transmembrane domains and the “pr” peptide which dissociates from 
the viral surface at neutral pH after secretion of the mature viral particle (57, 109). In 
addition to viral particles, subviral particles (slowly sedimenting hemagglutinin-SHA) 
are also produced upon natural infection. Subviral particles lack a nucleocapsid, are 
smaller than the virion, (diameter of approximately 30nm), and the mature secreted 
forms contain only 30 E protein dimers on the surface. They can also be produced in 
a recombinant form as so-called recombinant subviral particles (RSPs) by 
transfection of mammalian cells with a prM-E encoding DNA expression vector (2). 
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Fig. 1.4 Schematic representation of the flavivirus life cycle 
Sequential steps of infection, replication, assembly, maturation and release are indicated. ER, 
endoplasmic reticulum; TGN, trans-Golgi network; SHA, slowly sedimenting hemagglutinin 
representing nucleocapsidless subviral particles. Figure adapted from (93). 
 
 
1.3.4 Viral structural proteins 
 
1.3.4.1 Surface glycoprotein E 
 
The E protein, the major constituent of the virion surface, serves as the ligand for 
the attachment of the virus to cellular receptors and mediates fusion of the cellular 
and viral membrane in the endosome after receptor-mediated endocytosis of the 
virus. Because of these functions, the E protein is the major inducer of a neutralizing 
and protective antibody response (for further details see section 1.4). 
It consists of approximately 500 amino acids and has a molecular mass of ~53 kilo 
Daltons (kDa). E is anchored in the viral membrane by two transmembrane alpha 
helices followed by the hydrophobic membrane proximal ‘stem’ region (Fig. 1.5B). 
The stem consists of two hydrophobic alpha helices which lie parallel to the 
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membrane and link the transmembrane parts and the ectodomain (110) (Fig. 1.5B). 
Crystal structures of soluble forms of the E protein (sE) from TBE, WN and DEN 
viruses, lacking the hydrophobic C-terminal stem and transmembrane regions, show 
that the E protein is organized into three distinct structural domains: domain I (DI) 
domain II (DII) and domain III (DIII) (45, 64, 65, 68, 79) (Fig 1.5A). DI is the central 
domain and is flanked by DII and DIII. It contains the glycosylation site(s) and two 
disulfide bridges and is mainly composed of ß-sheets and random coils (Fig 1.5A). 
DII is a finger-like structure, formed by two elongated loops emanating from DI, 
containing three disulfide bonds and, in addition to ß-sheets and random coils, also a 
short alpha helix. At its tip, DII contains the fusion peptide (FP) loop (Fig 1.5A), which 
is highly conserved among flaviviruses and an important functional element in the 
early stages of viral and endosomal membrane fusion (Fig. 1.4). Upon exposure to 
acidic pH in the endosome, the FP loop gets exposed and makes contact with the 
endosomal membrane thus initiating the fusion process (93). DIII is located at the C-
terminal end of the protein (Fig 1.5A). It is non-glycosylated and contains a single 
disulfide bridge which is the critical determinant for proper folding of DIII (84). It is 
composed of ß-sheets and random coils and adopts an Ig-like fold. DIII is the putative 
receptor binding domain (6, 13, 17). 
The surface structure of flavivirus virions was determined by cryo-EM and image 
reconstructions using fitting of the crystal structures of soluble E proteins from DEN 
and WN viruses into the electron density of the virions (51, 66, 110) revealing the 
structural organization of the E protein on the surface of immature and mature viral 
particles, respectively (Fig. 1.5C and D). 
 
 21     
Introduction 
 
 
Fig. 1.5 Structural organization of the E protein in its isolated form and on the surface of viral 
particles. 
(A) Ribbon diagram of the WN virus sE monomer, top and side view (68). The lateral ridge of DIII (DIII-
lr) is highlighted in cyan and glycosylation (CHO) is indicated in grey. 
(B) Schematic representation of the E protein dimer, top and side view (93). The membrane-proximal 
stem region is shown in blue (Helix 1, 2) and purple (linker) and the transmembrane helices are shown 
in green. In all panels, DI is indicated in red, DII in yellow and DIII in blue. The fusion peptide (FP) is 
shown in orange.  
(C) Surface structure of immature flaviviruses based on fitting of the crystal structures of soluble E 
proteins into the cryo-EM electron density of the particle, showing the spiky projections formed by the 
E-prM heterodimers (60). 
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(D) Surface structure of mature flaviviruses based on fitting of the crystal structures of soluble E 
proteins into the cryo-EM electron density of the particle, showing the herring bone-like arrangement of 
the E protein dimers (60). Figure adapted from (60, 93). 
Schematics of an isolated monomer, an E dimer and a raft of three E dimers are depicted between 
panels C and D. 
 
 
1.3.4.2 Surface glycoproteins prM/M 
 
The envelope glycoprotein prM is the precursor of the M protein. prM has a 
molecular mass of about 26 kDa and is anchored in the viral membrane via two alpha 
helices (Fig. 1.3). During biosynthesis of the structural proteins in the host cell, prM 
folds independently and is believed to serve as a chaperone for the correct folding of 
the E protein (62). In immature virions, prM forms heterodimers with the E protein. 
This interaction shields the fusion peptide at the tip of DII of E (Fig. 1.3 and 1.4) and 
prevents E from initiating premature fusion of the viral with host cell membranes upon 
encountering acidic pH in the TGN during the process of secretion (Fig 1.4). In the 
TGN, prM gets cleaved by the host serine protease furin into the pr and the M 
protein. Following cleavage and secretion of the viral particle, the pr part falls off 
upon neutral pH into the extra cellular milieu (57, 109). 
 
 
1.3.4.3 Capsid protein C 
 
The capsid protein is a highly basic protein with a molecular mass of about 11kDa. 
Crystal structures have shown that the positively charged residues, which are 
clustered at the C and N termini, are separated by a hydrophobic stretch and that the 
basic building blocks of the viral capsid are C protein dimers (22, 49). The molecular 
architecture of C suggests that the hydrophobic part is involved in interaction with the 
viral membrane and the positively charged part in interaction with the negatively 
charged RNA genome (22). 
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1.4 The antibody response to flaviviruses  
 
Infections with flaviviruses induce antibodies which are specific for structural as 
well as non-structural proteins. So far, antibodies specific for E, prM/M, C, NS1, NS3 
and NS5 have been described (5, 21, 75, 98, 106). Because of its important functions 
in the flavivirus life cycle, the E protein is the major inducer of virus neutralizing and 
protective antibodies. Antibodies to prM can also lead to neutralization, presumably 
through the interaction with partially mature virions (24, 46). NS1-specific antibodies 
seem to protect via a complement mediated effector mechanism such as reviewed in 
(21). Using monoclonal antibodies, binding sites of neutralizing antibodies were 
identified in all three domains of the E protein (4, 15, 30, 38, 69, 70, 82, 83, 87, 96, 
98, 107). As reviewed in (82) and (21), DIII contains epitopes of flavivirus type-
specific and/or serocomplex-specific antibodies with a high neutralizing potency. 
Studies with mouse monoclonal antibodies (mabs) suggest that the most potent 
antibodies bind to the highly surface-exposed upper lateral ridge of DIII (DIII-lr; Fig. 
1.5A), as it was shown for WN (69) and DEN viruses (30). The E protein also induces 
broadly flavivirus cross-reactive antibodies which react even with distantly related 
flaviviruses from different serocomplexes (Fig. 1.1) but do not, or not completely, 
neutralize virus infectivity at physiological antibody concentrations (67, 72, 87, 94). It 
was shown that broadly cross-reactive antibodies predominantly bind to a region 
containing the fusion peptide (FP), which is located at the tip of DII of the E protein 
(Fig. 1.3A) (15, 72, 94). The physical explanation for the moderate or lacking 
neutralizing activity of such antibodies is that the fusion peptide is occluded in mature 
infectious virions, and therefore not or only poorly accessible for antibody binding 
(94). As a further evidence, cryo-EM studies of West Nile virus in complex with FP-
specific monoclonal antibody E53 indicated that some antibodies seem to bind more 
efficiently to spikes in immature flaviviruses but not to mature virions, suggesting that 
the FP-loop is more accessible for antibody binding in the prM-E heterodimer than in 
the E homodimer (11). 
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1.4.1 Mechanism of antibody-mediated flavivirus neutralization 
 
The neutralizing potential of an antibody is dependent on the affinity for its target 
and on the localization and accessibility of the epitope on the viral surface. 
Neutralization of virus infectivity is achieved when a certain threshold of bound 
antibodies is exceeded (76). Surface-exposed epitopes like the lateral ridge in DIII 
(DIII-lr; Fig. 1.5A) require a smaller fractional occupancy than poorly accessible ones, 
as it is the case with the FP loop in DII (Fig. 1.5A) recognized by broadly cross-
reactive antibodies. Neutralisation of infectivity is achieved by preventing functional 
activities of the E protein, like attachment to the host cell by direct blocking of 
receptor binding, and/or membrane fusion in the endosome (69, 97, 101). In vivo, 
additional mechanisms, for instance Fc-receptor and complement-mediated effector 
functions induced by virus-antibody complexes contribute to protection (75). 
 
 
1.4.2 Fine-specificity of the polyclonal antibody response to the viral envelope 
protein E 
 
The E protein is the major surface antigen of flaviviruses and the major target of 
virus neutralizing and protective antibodies. Analyses of the fine-specificity of the 
polyclonal antibody responses to important functional determinants of the E protein, 
like the FP loop and DIII (Fig. 1.5A), in post-infection sera of humans, mice, and 
horses revealed significant differences among the different species. Mice 
experimentally infected with West Nile virus showed induction of a high proportion of 
DIII-specific antibodies, which contributed significantly to WNV neutralization (71). In 
contrast, no significant proportions of DII FP loop-specific antibodies were detected. 
Analysis of human and equine DEN and WN virus post-infection sera showed that 
DIII-specific antibodies are not as dominant as in mice but represent only a minor 
fraction of the total antibody response (5, 71, 86, 98, 104). In some cases, DIII-
specific antibodies contributed significantly to neutralization in humans or horses (16, 
86). In contrast to mice, human post-infection sera showed that DII FP-specific 
antibodies comprise a major fraction in the polyclonal antibody response (16, 53, 71, 
98). 
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Compared to E, antibody responses to the structural proteins prM/M contribute 
less to virus neutralization. Monoclonal antibodies isolated from mice and humans 
specific for prM showed poor or no neutralizing activity in vitro and protective efficacy 
in vivo (5, 24, 44, 46, 98). In infected humans, prM antibodies represent only a minor 
fraction of the total antibody response (5, 53, 98) to infection with DEN or WN 
viruses. In the case of dengue virus infections, however, antibodies to prM are 
believed to contribute to an infection–enhancement phenomenon leading to dengue 
hemorrhagic fever (DHF) or dengue shock syndrome (DSS) (19, 44, 81). 
 
 
1.4.3 Vaccination strategies for the induction of a neutralizing antibody 
response 
 
Different vaccination strategies to prevent disease caused by flavivirus infection 
have been pursued in past decades. Until now, vaccines against Japanese (formalin 
inactivated whole virus and live attenuated), tick-borne encephalitis (formalin 
inactivated whole virus) and Yellow fever (live attenuated) have been successfully 
applied in humans (77). Currently, no vaccines against dengue or West Nile viruses 
are available for humans. For horses, however, WN vaccines (inactivated whole 
virus, recombinant DNA, live chimeric virus) have been licensed and are currently in 
use (18). 
Alternative approaches which are currently under investigation include 
recombinant DNA vaccines (78), recombinant subviral particles (37, 61), soluble 
recombinant antigens (14, 34, 59) and genetically engineered live attenuated viruses. 
The latter are based on the established YF virus vaccine strain 17D in which the 
genes coding for prM and E are replaced by the corresponding sequences of 
heterologous flaviviruses, e.g. JE, DEN or WN viruses (chimeric viruses) (33). 
In the context of this thesis, the major interest was in the use of recombinant 
soluble forms of the E protein (sE) or isolated DIII as immunogens. For immunization 
of mice (7, 14, 56, 58) monkeys (14, 59, 80) or hamsters (7, 105), recombinant sE 
proteins from WN and DEN viruses were produced primarily in insect cells. To 
increase the immunogenicity, sE was administered in combination with adjuvants like 
Freunds aduvant (14, 56), ISCOMATRIX (105) or aluminium hydroxide (7, 14, 56, 
80). Collectively these studies showed that sE induced virus neutralizing antibodies 
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which were partly or completely protective in vivo as demonstrated by viral challenge 
of immunized animals. 
In the case of recombinant DIII, additional attempts to increase the 
immunogenicity included not only the application of adjuvants but also the use of 
heterologous fusion partners (1, 108), expression on viral carriers (48, 92) and strings 
composed of multiple copies of DIII (10, 47). Administration of high doses of up to 
100µg per immunization, the use of strong adjuvants and the administration of at 
least 2-3 doses were generally required to induce a measurable neutralizing DIII-
specific antibody response. Even then, only partial protection from viral challenge 
could be achieved (1, 12, 40, 89, 108). 
Recombinant antigens were not only administered as single antigens but also 
used in prime-boost vaccination regimens to increase the level and the persistence of 
neutralizing antibodies. In mice and monkeys, combinations of a DNA vaccine 
encoding DEN sE, a recombinant DEN DIII fusion protein, with maltose binding 
protein as a fusion partner, and inactivated whole DEN virus were compared to the 
single antigens alone (88, 90). However, the chosen prime-boost strategies did not 
result in an increased neutralizing antibody response compared to homologous 
immunizations with the DIII protein or the inactivated virus alone. In another study 
(99) monkeys were primed with recombinant DEN virus DIII and boosted with 
infectious DEN virus or vice versa. Both regimens did not yield higher antibody titers 
compared to infection without DIII priming. 
 
 
1.4.4 Influence of pre-existing antibodies on subsequent responses to 
infection or immunization 
 
Pre-existing antibodies, acquired either by infection or immunization, can have an 
impact on the antibody response to subsequently encountered related antigens. In 
general, inhibition as well as enhancement of the antibody responses have been 
observed. These phenomena were termed ‘Original Antigenic Sin’ (OAS) and 
‘antibody-mediated feedback regulation’. 
OAS describes the finding that sequential infections or immunizations with cross-
reactive antigens can lead to an accelerated response to the original antigen. In 
particular, memory responses to epitopes which are shared by the cross-reactive 
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antigens are primarily activated, whereas the primary response to other epitopes of 
the subsequently encountered antigen can be impaired or delayed. This 
phenomenon was originally described for sequential infections with different influenza 
virus strains in humans (27). OAS phenomena in the context of infections or 
immunizations with flaviviruses have been described for sequential dengue virus 
infections with different serotypes (36) or TBE virus vaccination of a YF virus immune 
individual (43). 
Pre-existing serum antibodies can form immune complexes with subsequently 
encountered antigens and either inhibit or enhance the antibody response by 
different mechanisms summarized under the term ‘antibody mediated feedback 
regulation’ (42, 74). Several possibilities were proposed how antigen in complex with 
immunoglobulin G (IgG) can mediate the suppression of antibody responses, 
primarily by preventing B-cell activation. First of all, immunoglobulin associated with 
antigens can mask the respective epitopes by making them inaccessible and 
therefore prevent the recognition by, and the activation of specific B-cells. Secondly, 
immune complexes can bind to Fc-gamma receptors (FcyR), for instance on 
macrophages or dendritic cells, inducing the internalization of the complex thus 
eliminating the antigen. Finally, cross-linking of the B-cell receptor with inhibitory 
motifs in the FcyIIB receptor can inhibit the activation of specific B-cells and 
subsequently, the production of specific antibodies. 
Enhancement of antibody responses as a result of the association of immune 
complexes with activating Fcy receptors on B-cells thus inducing their activation, is a 
well established mechanism (41). 
 
 
1.5 Recombinant protein expression 
 
Recombinant proteins can be produced in a variety of different and commercially 
available expression systems. In general, cell-free and cell-based systems can be 
distinguished. The cell free systems, in which proteins are synthesized in an in vitro 
reaction, are expensive and do not achieve the high protein yields of cellular 
expression systems. Therefore they are of minor relevance and not discussed 
further. The choice of a suitable expression system with respect to the production of 
proteins for immunization depends on the specific characteristics of the proteins like 
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folding properties and post-translational modifications, as well as the required yield 
and the desired application.  
 
 
1.5.1 Heterologous protein expression in prokaryotic cells 
 
In general, bacterial expression is suitable for the production of small, self folding 
proteins without any post-translational modifications. The advantages are the fast 
growth rates of bacteria and the high expression level of the recombinant protein of 
up to or even more than 50 % of the total cellular protein. In addition, cultures are 
relatively easy to handle and production is cheap. A limitation of this approach is that 
commonly used expression hosts like E.coli do not have the machinery for proper 
post-translational modifications like glycosylation which can have an impact on the 
folding and functionality of the protein. In addition, the highly over-expressed 
recombinant proteins tend to aggregate in the bacterial cell, forming so-called 
insoluble ‘inclusion bodies’. Solubilisation from the insoluble phase and refolding of 
solubilised material is possible but there is a chance to obtain misfolded protein. 
Strategies to circumvent this problem are the use of fusion partners which can 
enhance the solubility (Nus-, GST- or thioredoxin-tags) of the proteins. For 
flaviviruses, properly folded DIII proteins were produced successfully in bacteria (6, 
69, 80, 102, 103). 
 
 
1.5.2 Heterologous protein expression in eukaryotic cells 
 
Compared to bacteria, high yield expression systems using eukaryotic cells have 
the advantage that recombinant proteins are properly post-translationally processed 
(e.g. glycosylation, phosphorylation or the addition of fatty acids) which can impact 
the folding, stability and thus the functionality of the protein. In addition, inclusion 
bodies are not formed in the cytosol. However, culturing cells is more expensive and 
mostly more demanding and expression levels are not as high as it is the case with 
bacteria. Yeast, insect, and mammalian cells have successfully been applied for the 
production of recombinant flavivirus proteins. 
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1.5.2.1 Protein expression in yeast  
 
Using yeast expression systems, recombinant proteins can either be produced as 
soluble forms, which are secreted into the culture medium and purified, or as 
transmembrane forms which are displayed on the yeast cell surface. This method, 
the so-called “yeast surface display”, is a widely used assay format to study protein-
protein interactions, including epitope mapping with monoclonal antibodies (mabs) 
(70, 72, 95, 96). Post-translational modifications like glycosylation can differ from 
those in higher eukaryotes like insect or mammalian cells. Subviral particles (61), DIII 
(23) as well as sE proteins (100) were produced in the yeast Pichia Pastoris and 
obtained in a proper conformation. 
 
 
1.5.2.2 Protein expression in insect cells 
 
Insect cells are able to perform post-translational modifications of proteins 
(glycosylation, acylation, disulfide bond formation, proteolytic processing and 
oligomerisation) similar to mammalian cells, and thus represent suitable hosts for the 
production of biologically active proteins in its proper conformation. Cells can be 
grown at a high density in suspension cultures, which can easily be scaled up. The 
two most widely used expression systems are the Drosophila expression system 
using Drosophila melanogaster cells and the Baculovirus expression system using 
Spodoptera frugiperda cells. The Drosophila expression system allows the stable 
transfection of the host cells for continuous production of recombinant proteins. The 
baculovirus expression system uses a lytic recombinant virus (Baculovirus) as a 
vector to deliver the recombinant gene into the host cell. Both systems were used to 
produce flavivirus proteins for different purposes like structural studies or the 
production of antigens for ELISA and immunization experiments. As demonstrated by 
the crystallization of sE proteins from DEN (64, 65) and WN viruses (45, 68) 
produced in Drosophila and Spodoptera cells, respectively, both systems are suitable 
to produce sE proteins with a proper conformation. In immunization studies it was 
shown that recombinant sEs could elicit a strong specific and neutralizing antibody 
response (7, 14, 56, 58). 
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1.5.2.3 Protein expression in mammalian cells 
 
Mammalian cells have a highly advanced protein processing machinery and 
therefore ensure the production of recombinant proteins with proper post-translational 
modifications, conformation and functionality. For example, complex post-
translational modifications like special types of N-linked glycosylation are only 
possible in mammalian cells and may be necessary especially for the production of 
recombinant proteins of mammalian origin. Disadvantages are often low yield, 
relatively slow cell growth and demanding cell culture. The most widely used cell 
types are CHO, HeLa, Cos-1 or HEK 293T cells. In the case of flaviviruses, 
recombinant subviral particles (RSPs) have been produced in HeLa (50) and Cos-1 
(2, 26, 28) cells, which were also used for the expression of soluble E (37). 
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2. Objectives 
 
E protein specific antibodies induced by infection or immunization are the major 
mediators of neutralization and protection against flaviviruses. The determination of 
the atomic structure of the E protein together with epitope mapping studies using 
monoclonal antibodies revealed that the E protein induces antibody populations with 
different functional characteristics, depending on the location of the epitope on the 
protein. Serocomplex or virus specific antibodies, some of which are known to be the 
most strongly neutralizing antibodies described so far, map to highly surface-exposed 
regions of DIII. In contrast, broadly flavivirus cross-reactive antibodies, which are only 
weakly or non-neutralizing, mainly bind to a region including the fusion peptide (FP) 
in DII. It is currently unknown whether there is an immunodominance of specific 
structural entities of E in the course of a polyclonal immune response induced by 
immunizations with inactivated virus and recombinant subunit antigens of flaviviruses. 
The main goal of this thesis was to investigate whether immunodominance and 
functional quality of the antibody response to E, or individual antigenic regions of E, 
are influenced by the structural context in which the antigen is presented to the 
immune system (formalin inactivated whole virus vs. soluble E vs. isolated DIII). It 
was a further objective to study if the antibody response can artificially be focussed to 
targets of highly neutralizing antibodies by the application of specifically designed 
prime-boost immunization regimens. Such strategies could have possible 
implications for future vaccine design. For those purposes, mice were immunized 
with different combinations of whole inactivated virus, recombinant soluble sE and 
isolated DIII of West Nile virus and the contribution of DIII- and FP-specific antibodies 
to the total neutralizing antibody response was analyzed. 
In order to accomplish these goals, the thesis had to be structured into four sub-
projects. The first part was dedicated to the production and characterization of 
recombinant sE and DIII proteins for the immunization of mice and for the use as 
antigens in immunological assays. Secondly, the conditions to elicit a robust antibody 
response with the recombinant sE and DIII antigens in mice were determined in a 
preliminary dose-finding immunization experiment. In order to be able to analyze the 
fine specificity / immunodominance of the antibody responses in mice, immunological 
assays such as different ELISA or antibody depletion formats were developed. In the 
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last part of the thesis, sequential prime-boost immunization regimes were applied in 
mice using the WN virus antigens and the resulting antibody responses were 
analyzed with an array of functional and binding assays. 
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ABSTRACT 
 
Factors controlling the dominance of antibody responses to specific sites in viruses 
and/or protein antigens are ill-defined but can be of great importance for the induction 
of potent immune responses to vaccines. West Nile virus and other related important 
human-pathogenic flaviviruses display the major target of neutralizing antibodies, the 
E protein, in an icosahedral shell at the virion surface. Potent neutralizing antibodies 
were shown to react with the upper surface of domain III (DIII) of this protein. Using 
the West Nile virus system, we conducted a study on the immunodominance and 
functional quality of E-specific antibody responses after immunization of mice with 
soluble protein E (sE) and isolated DIII in comparison to inactivated whole virions. 
With both virion and sE, the neutralizing response was dominated by DIII-specific 
antibodies but the functionality of these antibodies was almost 4 times higher after 
virion immunization. Antibodies induced by the isolated DIII had an at least 15-fold 
lower specific neutralizing activity compared to the virion and only 50% of these 
antibodies were able to bind to virus particles. Our results suggest that immunization 
with the tightly packed E in virions focuses the DIII antibody response to the 
externally exposed sites of this domain which are the primary targets for virus 
neutralization, different to sE and isolated DIII which also display protein surfaces 
that are cryptic in the virion. Despite its low potency for priming, DIII was an excellent 
boosting antigen, suggesting novel vaccination strategies that strengthen and focus 
the antibody response to critical neutralizing sites in DIII. 
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INTRODUCTION 
 
The availability of high resolution structures is a pre-requisite for understanding 
structural determinants of immunogenicity and immunodominance. Knowledge of 
factors that control and/or influence these properties of antigens can lead to an 
improvement of existing vaccines and the rational design of new vaccine antigens 
and regimens (13). Flaviviruses are among those human-pathogenic viruses for 
which detailed structural information is available through the combined use of X-ray 
crystallography and cryo-electron microscopy (cryo-EM) (25, 30, 36-38, 40, 49, 65). 
The most important representatives are the mosquito-borne yellow fever (YF), 
dengue (DEN), Japanese encephalitis (JE), and West Nile (WN) viruses, as well as 
tick-borne encephalitis (TBE) virus (14). These viruses have a significant impact on 
public health and the potential for emergence in new geographic regions, as 
exemplified by the expansion of WN virus in the Americas since its first introduction 
to the USA in 1999 (17). Human vaccines are in general use against YF (live 
attenuated), JE (live attenuated and inactivated whole virus), and TBE (inactivated 
whole virus) but not yet against DEN and WN viruses (48). 
Mature flavi-virions are composed of an isometric capsid containing the positive-
stranded RNA genome and a lipid envelope with two membrane-associated proteins, 
E and M (33). As revealed by cryo-EM, 90 copies of E protein dimers (oriented 
parallel to the viral membrane) form a tight shell at the virion surface in a 
herringbone-like arrangement (30, 38) (Fig. 1A). Because of its dual function in 
receptor binding and acid pH-induced membrane fusion (33), E is the major target of 
virus-neutralizing antibodies that mediate protection and long-lived immunity, both 
after natural infection and vaccination (12, 46, 47, 50). Each of the monomeric 
subunits of E contains three distinct domains, designated DI, DII, and DIII (Fig. 1B). 
The central DI is flanked by DII, carrying the highly conserved internal fusion peptide 
(FP) loop, and by DIII, which has an immunoglobulin-like fold. DIII protrudes slightly 
off the relatively smooth surface of mature virions and has been implicated in 
receptor-binding (6, 9, 32). The rest of the molecule, which is absent from the crystal 
structures, comprises the so-called stem that follows DIII and leads to the double 
membrane-spanning anchor at the C-terminus of the molecule. 
Epitopes involved in virus neutralization have been identified in each of the three 
domains, at sites exposed at the virion surface (3, 10, 16, 20, 29, 41, 44, 50, 51, 58, 
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59, 63). Studies with mouse monoclonal antibodies suggest that the most potent 
neutralizing antibodies are virus type-specific and bind to the highly variable upper 
lateral ridge of DIII (16, 42). Antibodies to the conserved FP loop, on the other hand, 
are broadly flavivirus cross-reactive but display comparatively low neutralizing activity 
(44, 57). 
A significant degree of heterogeneity in the specificities of antibody populations 
was observed with mouse, human, and horse post-infection and/or post-
immunization sera (11, 31, 43, 52, 59, 62). Antibodies to DIII made up a significant 
fraction of the IgG response in mice, but only a small proportion in humans in whom 
the response was dominated by antibodies to the FP loop (11, 31, 43, 59). Factors 
that control the immundominance of antibody responses are ill-defined but, in 
addition to host-specific factors, may be influenced by the physical organization of the 
antigen and differences in the presentation of antigenic protein surfaces during 
immunization. The specific design and selection of antigens can also provide clues to 
the development of vaccines against highly variable pathogens, such as HIV or 
influenza viruses (15, 55, 61). 
Considering the many unresolved questions of immunodominance, we conducted 
a mouse immunization study - using the WN virus system - in which we investigated 
whether and in which way the fine-specificity of antibody responses to E, especially 
the contribution of DIII antibodies, was influenced by the quaternary organization of 
the immunogen, i.e. E in its isolated monomeric form (sE) as compared to E tightly 
packed in whole inactivated virus. We also assessed whether it is possible to 
specifically focus and strengthen the antibody response to DIII by i. boosting with 
isolated DIII after priming with inactivated virion or sE and ii. priming with isolated DIII 
followed by boosting with inactivated virion or sE. We demonstrate that inactivated 
virions induced DIII-reactive antibodies with higher specific neutralizing activity than 
sE and that in both cases antibodies to this domain dominated the total neutralizing 
activity. We also show that the isolated DIII is an excellent booster antigen which 
restimulates DIII-specific and neutralizing antibodies after priming with virion or sE 
more strongly than the homologous priming antigens. Paradoxically, priming with DIII 
followed by boosting with virion or sE had no beneficial effect but – in contrast - 
resulted in dampening of the antibody response. Our data suggest that the 
neutralizing immune response to flavivirus vaccines may be focused and optimized, 
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after appropriate priming, by booster vaccinations with preparations of recombinant 
DIII. 
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MATERIALS AND METHODS 
 
Production of purified inactivated WN virus. Virus production was carried out 
essentially as described in (21) for tick-borne encephalitis virus. In brief, primary 
chicken embryo cells were infected with WN virus, strain NY99 (GenBank# 
AF196835). 24 hours p.i. the cell supernatant was harvested, clarified by 
centrifugation and inactivated with formalin (1:2000) for 24 hrs at 37°C. The 
inactivated virus was concentrated by ultracentrifugation and purified by rate zonal 
followed by equilibrium sucrose density gradient centrifugation. SDS-PAGE analysis 
indicated the presence of a small proportion of uncleaved prM, as is characteristic for 
purified preparations of WNV (8) and for flaviviruses in general (24) as well as 
oligomeric bands of C and E as a result of formalin cross-linking (Fig. 1D). 
 
Expression and purification of WN and TBE virus sE. Recombinant E proteins 
from WN virus strain NY99 and TBE virus strain Neudoerfl (GenBank# U27495) were 
expressed in Schneider 2 (S2) cells using the pMTBip/V5-His vector (Invitrogen) and 
inserts containing the coding sequences for prM and E (C-terminally truncated after 
amino acid 400). For immunization, the WN virus sE was produced without His-tag by 
the introduction of a stop codon after amino acid 400. Blasticidin-resistance was used 
for the selection of stably transfected cells according to the manufacturer’s 
instructions. Expression was induced by CuSO4 and the supernatants were 
harvested 7 to 11 days post-induction. Recombinant proteins were purified by 
immuno-affinity chromatography using the flavivirus cross-reactive monoclonal 
antibody 4G2 (ATCC# HB-112). The purity of the recombinant sE proteins was 
>95%, as determined by SDS-PAGE and densitometric analysis (Fig. 1D). 
 
Expression and purification of WN virus recombinant DIII. DIII of WN virus 
strain NY99, encompassing amino acids 300 to 399 of E, was expressed with and 
without a C-terminal His-tag (including a stop codon after amino acid 399) in 
Escherichia coli strain BL21 using the pET 32a Xa/LIC vector (Novagen) as a fusion 
protein with thioredoxin. For purification of soluble DIII without a C-terminal His tag, 
the fusion protein in clarified cell lysates was bound to a Ni++-immobilized affinity 
column (GE Healthcare Life Sciences) via the internal His-tag located between 
thioredoxin and DIII, and DIII was eluted from the column after proteolytic cleavage 
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from thioredoxin by factor Xa protease. For expressing C-terminally His-tagged DIII, 
the internal His-tag was deleted from the expression cassette so that the fusion 
protein bound to the affinity column via the C-terminal His tag of DIII. The thioredoxin 
fusion partner was cleaved off by factor Xa, removed by washing the column, and 
DIII was specifically eluted by an imidazole gradient. Final purification was 
accomplished by anion exchange chromatography using Sepharose Q columns (GE 
Healthcare Life Sciences) according to the manufacturer’s instructions. By SDS gel 
analysis, a single band corresponding to DIII was visible by Coomassie staining (Fig. 
1D). 
 
Mouse immunization experiments. Mouse experiments were carried out in strict 
accordance with the guidelines of the Federation of European Laboratory Animal 
Science Associations (FELASA) and the Austrian federal law. The protocol was 
approved by the ethics committee of the Medical University of Vienna and the 
Austrian Federal Ministry of Science and Research (Permit Number: BMWF-
66.009/0068-II/10b/2008). Six to eight weeks old C57BL/6 mice (Charles River 
Laboratories) were immunized sub-cutaneously with inactivated virus, sE or DIII, 
adsorbed to 0.2% Al(OH)3 (Aluminum hydroxide gel, Sigma) in 100µl buffer 
containing 0.05M triethanloamine, 0.1M NaCl, pH 8.0, at doses of 1µg, 5µg and 20µg 
per immunization, respectively. Blood was taken from the tail vein at the time points 
indicated in Fig. 1E and F, using microvette 200 capillaries (Sarstedt). Antibody 
analyses were carried out using pools of sera from the groups of mice with the same 
immunization schedule. 
 
Virion ELISA. Microtiter plates were coated with formalin-inactivated purified WN 
virus at a concentration of 0.35 μg/ml in carbonate buffer, pH 9.6, at 4°C. Serial 
three-fold dilutions of pooled mouse sera, starting at a dilution of 1:100, were added 
to the plates and incubated for 1h at 37°C. As negative controls, sera from naïve 
mice were included. The bound antibodies were then detected using peroxidase-
labeled rabbit anti-mouse immunoglobulin G as described in (57). Titration curves 
were established using Graph pad Prism 5 software and serum titers were defined at 
an absorbance (490 nm) cut-off of 0.35, as deduced from the analysis of negative 
control sera. Each serum pool was tested in at least three independent experiments, 
and results are presented as the geometric means of these repetitive experiments. 
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Analysis of avidity in virion ELISA. Samples were analyzed in the standard 
virion ELISA, except that an additional washing step with and without 6M urea in the 
washing buffer was applied after serum incubation, essentially as described by (56). 
Titers were determined at an absorbance cut-off of 1.0 after curve-fitting using a four-
parameter logistic regression (GraphPad Prism 5.0). Relative avidities are expressed 
as percentage of the titer obtained in the presence of urea compared to the titer in 
the absence of urea. 
 
sE and DIII ELISA. Microtiter plates were coated with rabbit anti-His-tag IgG 
antibody (QED Bioscience), at 4°C in carbonate buffer, pH 9.6. DIII-His or sE-His 
proteins were added at a concentration of 1 and 0.5 µg/ml, respectively, and 
incubated for 1h at 37°C. Three-fold serial dilutions (starting at 1:100) of pooled 
mouse sera were then added for 1h at 37°C. As negative controls, sera from naïve 
mice were included. The bound antibodies were detected using peroxidase-labeled 
goat anti-mouse immunoglobulin G (Pierce) for 1h at 37°C. Visualization of bound 
antibodies and determination of serum titers were done as described for the virion 
ELISA. 
 
WN virus neutralization assay. WN virus neutralization assays were carried out 
in microtiter plates using Vero cells (ECACC #84113001). Pooled mouse sera were 
heat-inactivated at 56°C for 30 minutes and two-fold serial dilutions, starting at a 
dilution of 1:20, were incubated with 20-40 TCID50 of WN virus, strain NY99, for 1h at 
37°C. The virus antibody mixture was then transferred onto Vero cells, and incubated 
for 4 days at 37°C. The cells were fixed with 4% paraformaldehyde for 30 minutes at 
room temperature. After fixation, the cells were blocked and permeabilized with Tris-
buffered saline (TBS) (50 mM Tris; 150 mM NaCl, pH 7.6, containing 3% Non-fat dry 
milk, 0.5% Triton X-100 and 0.05% Tween-20) for 30 minutes at 37°C, and a WN 
virus specific rabbit serum was added for 1.5h at 37°C. Bound antibodies were 
detected with alkaline phosphatase labeled anti rabbit IgG (Sigma) and SigmaFast 
pNNp (Sigma) as a substrate. The enzymatic reaction was stopped with 1.5N NaOH 
and absorbance was measured at 405 nm. Titers were determined after curve-fitting 
using a four-parameter logistic regression (GraphPad Prism 5.0) and a cut-off of 90% 
reduction of the absorbance in the absence of antibody (NT90). A cut-off of 50% 
(NT50) was not as robust in the lower titer range, since some negative sera would 
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have yielded false positive titers between 10 and 20. Each serum pool was tested in 
at least two independent experiments. 
 
Antibody depletion using WN virus DIII and TBE virus sE. One µg of His-
tagged WN virus DIII or TBE virus sE was incubated with 1mg paramagnetic 
‘Dynabeads His-Tag Isolation & Pull Down’ beads (Invitrogen) for 30 minutes at room 
temperature on an orbital shaker (1,000 rpm). After pelleting by magnetic force, the 
beads were resuspended in pull-down buffer according to the manufacturer’s 
instructions and incubated for 1h at 37°C with a 1:5 dilution of serum pools in PBS. 
The beads were pelleted again by magnetic force and the depleted serum was 
collected. To achieve quantitative depletion, this procedure was performed three 
times. Lack of non-specific binding of antibodies to the beads was confirmed by the 
incubation of mouse immune sera with unloaded beads and beads loaded with an 
unrelated His-tagged protein. 
 
Antibody depletion using WN virus. 10 µg of inactivated WN virus were 
incubated with pooled sera (diluted 1:50 in PBS pH 7.4, 0.1% BSA) for 1h at 37°C. 
The virus antibody complexes were pelleted by ultracentrifugation in a Beckman Ti90 
rotor at 50,000 rpm at 4°C for 1h. The supernatant was collected and used for further 
analyses. 
 
Statistical analyses. Data were analyzed with GraphPad Prism software, version 
5 (GraphPad Software Inc., San Diego). Two tailed t-tests were used to compare 
antibody titers, ratios of antibody titers and ELISA avidities. Differences were 
considered significant when the p value was less than 0.05. 
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RESULTS 
 
Characteristics of immunogens. Three different antigens of WN virus were 
used in our immunization studies (Fig. 1A-D) (see also Materials and Methods): 1. 
Highly purified formalin-inactivated virus. As revealed by cryo-EM studies with tick 
borne encephalitis virus (PhD thesis, S.T. Brady, University of Oxford, unpublished 
data), formalin inactivation does not affect the specific herring bone-like arrangement 
of 90 E protein dimers at the surface of mature virions. 2. Purified soluble 
recombinant E (sE) produced in S2 cells, shown to be a monomer by cross-linking 
and sedimentation analyses. Evidence for correct folding was obtained by the 
demonstration of the presence of S-S bridges by SDS-PAGE under reducing and 
non-reducing conditions (data not shown) 3. Purified recombinant DIII produced in 
bacteria. The presence of the single disulfide bridge was confirmed by mass 
spectrometry (data not shown). 
All three antigen preparations displayed similarly strong reactivities with the 
conformation-sensitive monoclonal antibodies (mabs) E16 and E24 (kindly provided 
by Michael S. Diamond; (42)) in the virion as well as the sE and DIII ELISAs as 
described in Materials and Methods (data not shown). 
Consistent with previous data (19), preliminary experiments had revealed that the 
inactivated virus had an at least 6-fold higher specific immunogenicity per µg of 
antigen than sE (data not shown). DIII alone did not yield significant titers even when 
used at a dose of 50µg. Therefore – in order to obtain measurable antibody 
responses and to be able to assess modulations in fine-specificity and 
immunodominance – Al(OH)3 was used as an adjuvant and different antigen doses 
per mouse were applied at each immunization as follows: inactivated virion: 1µg; sE: 
5µg; DIII: 20µg. 
 
Antibody response to virion, sE and DIII. For investigating the influence of the 
immunogens’ structural context (i.e. the same antigen tightly packed in virions or in 
soluble form) on fine specificity, dominance and functional activity of the antibody 
response, we immunized groups of mice twice with whole inactivated virus, the 
isolated sE and the isolated DIII (see immunization schedule in Fig. 1E). Eight weeks 
after the second immunization, blood samples were taken and pooled sera were 
analyzed in neutralization assays as well as in ELISAs using inactivated virus, sE, 
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DIII and the heterologous TBE virus sE as antigens (Fig. 2). Both, the inactivated 
virion and sE, induced neutralizing antibodies, but the titer was higher after virion 
immunization - despite the fact that the dose applied was only one fifth of that of sE 
(Fig. 2A). DIII, on the other hand, induced antibodies that were only partially 
neutralizing (NT50 titer of 35), and the extrapolation of the neutralization curve 
indicated that the NT90 titer was below 10. In ELISAs, the sera exhibited strikingly 
different patterns of reactivities with virion, sE, DIII and TBE virus sE (Fig. 2B), 
suggestive of differences in the fine-specificities of the antibody responses obtained. 
Most importantly, the E protein in the context of whole virions induced a lower 
proportion of DIII antibodies – relative to the total amount of virion reactive antibodies 
– than the isolated sE (Fig. 2C). 
 
Contribution of DIII-specific antibodies to virus neutralization. Because of the 
different ELISA ratios obtained after immunization with virion and sE (Fig. 2B and C) 
and the fact that the most potent neutralizing mabs described so far are directed to 
DIII (12, 46), we investigated the contribution of DIII-specific antibodies to 
neutralization by their removal with recombinant DIII bound to magnetic beads 
(Materials and Methods). As shown by DIII-ELISA, this procedure resulted in a 
virtually complete depletion of DIII-reactive antibodies from the serum pools (Fig. 3A); 
in virion ELISA, the drop of reactivity was 32% with the virion sera but as high as 
76% with sE sera (Fig. 3B). In both instances, however, about 75% of the neutralizing 
activity was removed and thus attributable to DIII-reactive antibodies (Fig. 3C). This 
discrepancy reflects significant differences in the specific neutralizing activities of 
DIII-reactive antibodies induced by virion and sE, expressed as ratios of DIII-
associated NT vs. DIII ELISA x 100 (Fig. 3D). These values were 1.5 and 0.4 after 
immunization with virion, and sE, respectively, and <0.1 after DIII immunization (no 
measureable NT90 titer). One possible explanation of these findings would be that E 
in its soluble form, and even more so the isolated DIII, would induce antibodies also 
to sites that are not highly exposed at the virion surface and thus contribute less to 
virus neutralization (46). 
To corroborate this hypothesis and to identify such antibodies, we depleted the 
three serum pools with whole inactivated virus and analyzed the resulting sera in 
virion and DIII ELISAs (Fig. 4A and B). With all three samples, the virus-reactive 
antibodies were almost completely removed by the procedure used (Fig. 4A). The 
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DIII ELISA revealed that about 50 % of the antibodies induced by DIII did not react 
with the virus in solution (Fig. 4B). Unexpectedly however, no difference was found 
between the virus- and sE-induced DIII-specific antibodies in this assay (Fig. 4B). A 
possible additional explanation of the lower functional activity of DIII-specific 
antibodies induced by sE and DIII compared to the virion could be related to 
differences in avidity for the virus. Such differences would be obscured in the 
depletion procedure because of the high excess of virus. We therefore analyzed the 
relative avidities of the sera in virion ELISAs using a urea wash step (Materials and 
Methods). As displayed in Fig.5, significant differences were found in the expected 
order, with the highest avidity for the antibodies induced by virus, followed by sE and 
DIII. 
 
Induction of broadly cross-reactive antibodies. Broadly cross-reactive 
antibodies directed to the highly conserved FP loop can make up a significant 
proportion of the polyclonal immune response to flaviviruses (11, 31, 43). For 
determining such antibodies, we analyzed the post-immunization sera in an ELISA 
with the heterologous TBE virus sE as an antigen. Overall, the WN virion and WNV 
sE post-immunization sera displayed only very low cross-reactive titers in this assay 
(Fig. 2B) and depletion with TBE virus sE did not measurably diminish their 
reactivities with WN virus sE (data not shown). There was also no evidence for cross-
neutralization in assays with TBE virus (data not shown). As expected, due to the 
lack of the conserved FP site, WNV DIII did not induce any detectable cross-reactive 
antibodies (Fig. 2B), consistent with previous studies on the antigenic specificity of 
DIII (4). 
 
Modulation of immunodominance by prime-boost regimens with DIII. In 
order to increase and strengthen the antibody response towards DIII and 
concomitantly the neutralizing potency of post-immunization sera, we conducted two 
sets of experiments: 1. mice primed with either virion or sE were boosted with DIII, 
and 2. mice were primed with DIII and boosted with virion or sE (compare 
immunization schedule in Fig. 1F). The resulting sera were pooled and analyzed in 
virion- and DIII-ELISAs as well as in virus neutralization assays. As shown in Fig. 6, 
DIII proved to be an excellent booster antigen, despite its low immunogenicity when 
used as a single immunogen (see Fig. 2A, B). In combination with inactivated virus 
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as well as with sE, it strongly boosted DIII- and virus-reactive antibodies in ELISA 
(Fig. 6A, B, D, E) which was associated with a strong increase of neutralizing activity 
(Fig. 6C, F). This effect was more pronounced with virion- than with sE-primed mice 
(Fig. 6A-C and D-F, respectively) and resulted in significantly higher neutralization 
titers as compared to the controls which received the inactivated virus for priming as 
well as for boosting (Fig. 6C). 
The alternative schedule, i.e. priming with DIII and boosting with virion or sE had 
a quite unexpected outcome. In both instances, pre-immunization with DIII resulted in 
an impairment of the antibody response - measured in ELISA and neutralization – as 
compared to unprimed controls (Fig. 7). 
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DISCUSSION 
 
When designing novel vaccines, it would be desirable to use immunogens and 
immunization schedules with an optimized immunological performance by focusing 
the response to those sites that are expected to induce the most potent neutralizing 
antibodies. This may be achieved by the selection or specific design of the 
immunogen (15, 55, 61) and/or by designing specific prime-boost regimens that 
direct and strengthen the immune response to most desirable functional parts of the 
antigen. In the case of flaviviruses, there is evidence (mostly from the analysis of 
mouse monoclonal antibodies (16, 42, 59)) that DIII of the envelope protein E can 
induce potent neutralizing antibodies which are directed to the upper lateral ridge of 
this domain (12, 47). 
In our study, we demonstrate that the functional quality of polyclonal DIII-specific 
antibody responses was strongly dependent on the structural context of this domain 
in the immunogen. The differences found were substantial. DIII-specific antibodies 
induced by the inactivated virus had an almost four-fold higher neutralizing activity 
(relative to the DIII ELISA titer; Fig. 3D) than those induced by soluble E. The 
discrepancy between ELISA-reactivity and functional activity was even more 
pronounced with antibodies induced by the isolated DIII which had a more than 15-
fold lower specific neutralizing activity than those obtained after virion immunization 
and failed to completely neutralize the virus. These differences were also reflected by 
the overall avidities of the antibodies to the virion which were shown to be highest 
after immunization with inactivated virus, intermediate with sE, and lowest with DIII. 
These findings are in agreement with a dengue type 2 immunization study in rhesus 
macaques (53) using inactivated virion, a DNA vaccine expressing prM and E, and a 
recombinant DIII-maltose-binding fusion protein. Also in this case, the antibodies 
induced by the inactivated virus had the highest avidity towards the virus and this 
property correlated with a reduction in the total days of viremia after challenge (53). 
It is likely that the phenomena observed in our study are related to differences in 
the exposure of antigenic sites in DIII and sE that are buried or less accessible in the 
virus. Antibodies to such sites may not reach an occupancy at the virion surface that 
is required for efficient neutralization (46). Inspection of the virion structure shows 
that DIII forms the highest protrusion in the mature virus, but that only a fraction of 
the total surface of DIII is accessible to the binding of antibodies. Substantial parts of 
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potentially antigenic sites are shielded in the context of the mature virion, specifically 
those at the bottom of the domain – directed towards the viral membrane – and those 
at its lateral sides because of interactions between E dimers in the tightly packed 
icosahedral envelope of the virus (Fig. 1A). The location of DIII epitopes as a decisive 
factor in virus neutralization is best exemplified by the WN virus-specific E16 mab 
that has been characterized by X-ray crystallography as well as cryo-EM (26, 41) and 
the mabs 5A2-7, 13D4-1 and E111 (raised against dengue virus) that have been 
mapped by yeast display combined with mutagenesis (58). E16 and related mabs are 
strongly neutralizing and bind to sites at the upper lateral ridge of DIII (Fig. 1C) that 
are highly accessible in the context of whole virions (16, 26, 41, 42). In contrast, the 
epitopes defined by mabs 5A2-7, 13D4-1 and E111 include the conserved AB loop at 
the bottom of DIII. This site is exposed in isolated or yeast-displayed DIII but has 
limited exposure in the context of the virus, because it is located inside the shell of E 
protein dimers and faces the viral membrane of the mature virion (58). The 
corresponding mabs therefore are poorly or not neutralizing. It has to be kept in mind 
however, that the E proteins in flaviviruses can undergo dynamic movements at the 
virion surface at 37°C (‘breathing’), thus allowing virus neutralization also by 
antibodies to partially occluded sites (34). Furthermore, the accessibility of antigenic 
sites may also be influenced by the presence of partially immature virions in the virus 
neutralization assay (39). Whether and to which extent such phenomena can also 
have an influence on the dominance of antibody responses to certain antigenic sites 
remains to be elucidated. 
The relative dominance of DIII-specific antibodies in our study (32% and even 
76% of the total antibody response after immunization with virion and sE, 
respectively) is consistent with other reports on antibody responses to flavivirus 
infections and immunizations in mice (43). In contrast, several studies with flavivirus-
infected humans (11, 31, 43, 59, 62) and horses (52) do not provide evidence for a 
dominance of DIII antibodies but suggest that the antibody response is skewed to 
potentially less potent epitopes in DI and DII, including the broadly cross-reactive 
fusion loop (11, 31, 43, 59). 
In the monomeric WN virus sE, the FP loop is highly exposed at the tip of DII (Fig. 
1B) (25, 40). It was therefore surprising that – like with whole virions – only low titers 
of broadly cross-reactive antibodies were induced by this antigen. In both instances, 
this response was minimal relative to the total anti-virion response. Given the strong 
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dominance of FP loop-specific antibodies reported in studies using human post-
infection sera (11, 31, 43, 59), this is an additional indication for significant 
differences between mice and humans in the immunodominance of individual 
epitopes. The factors responsible for directing the antibody response to selected sites 
at the surface of the same antigen in different species are unknown and will have to 
be elucidated for generating a more rational basis of engineering antigens for future 
vaccine design. 
Consistent with published data, the immunizing potency of DIII alone was low in 
our study and different attempts have been described in the literature to increase its 
immunogenicity (reviewed by (18)). This includes the use of fusion proteins (1, 22, 
35, 64), combinations with strong adjuvants such as Freund’s adjuvant (1, 2, 22, 35), 
the use of strings of DIII (7, 27), expression by adenovirus vectors (28), or the 
coupling to large carriers such as a bacteriophage (54) to mimic its presentation at 
the surface of the virus. However, despite its low immunogenicity when used alone, 
DIII proved to be an excellent boosting antigen and strongly enhanced the 
neutralizing antibody response of mice pre-immunized with inactivated virion or sE. In 
this respect, DIII was superior to the more complex immunogens used for priming. It 
is justified to assume that DIII (in the prime-boost regimen applied) primarily induced 
an anamnestic response to those sites of DIII presented at the virion surface that are 
relevant for virus neutralization. Considering the lack of immunodominance of DIII in 
humans, novel vaccination strategies could be based on the exploitation of the 
superior specific immunogenicity and priming capacity of inactivated virions 
combined with the excellent boosting capacity of DIII. Such an immunization regimen 
could foster the antibody response to the most relevant neutralizing site in the virus 
and thus potentially lead to a strengthening of the immunity induced by vaccination. 
Similar boosting approaches would also be possible in combination with live flavivirus 
vaccines (60). 
As an alternative for focusing the antibody response towards DIII, we also 
investigated a regimen of priming with recombinant DIII followed by boosting with the 
more complex antigens, i.e. virion and sE. Surprisingly, this schedule resulted in a 
significant negative effect on the total antibody response against the booster antigens 
and, most importantly, in an apparent impairment of the neutralizing response. 
Factors proposed to be involved in such negative effects include T cell mediated 
suppression, masking pre-existing antibody, or enhanced clearance of immune 
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complexes (13, 23, 45). The phenomenon observed may also be influenced by the 
specific combinations of doses and the immunization schedule used in our study, 
since opposite effects i.e. enhanced neutralizing antibody responses after priming 
with recombinant DIII followed by live virus infection were described in a dengue virus 
study (5). Possible effects of using different combinations of antigens, doses and live 
virus immunizations on the immunodominance of specific sites may be a topic of 
future investigations. In any case, our data point out that the use of the isolated DIII 
for priming can lead (at least under certain circumstances) to an unwanted negative 
effect and some caution should therefore be applied in such immunization regimens. 
Overall, our study emphasizes that the functionality of antibodies induced by WN 
virus antigens is not only dependent on their native conformation but also strongly 
influenced by their quaternary organization. The flavivirus particle displays the sites 
most relevant for virus neutralization at its surface, whereas other potentially 
antigenic faces of the envelope proteins are occluded due to their tight packing in an 
icosahedral lattice. Such sites, however, are exposed in isolated recombinant 
proteins which are therefore potentially prone to induce a higher proportion of 
antibodies that are irrelevant for neutralization. Despite its low specific 
immunogenicity when used alone, DIII could be superior as a booster vaccine 
compared to virion or sE, because it optimizes the development of neutralizing 
antibodies and leads to an increase of the immunodominance of the most critical 
neutralizing determinants in the virion. 
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FIGURES 
 
 
FIG 1. Immunogens and immunization schedules. (A) Schematic model of a 
flavivirus virus particle based on cryo-EM reconstructions of dengue and WN viruses 
(30, 38). The viral surface is covered by a densely packed shell consisting of 90 
copies of E protein dimers which are arranged in a herring bone-like lattice, 
consisting of 30 rafts of three E dimers. One of these rafts, an E dimer and an E 
monomer are depicted separately at the bottom of this panel. (B) Ribbon diagrams 
(top and side view) of the WN virus soluble E protein monomer (40), (pdb ID 2HG0). 
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(C) Ribbon diagrams (top and side view) of the WN virus DIII (40), (pdb ID 2HG0). In 
panels A, B and C, DI, DII and DIII of E are shown in red, yellow and blue, 
respectively. The fusion peptide (FP) loop at the tip of DII is highlighted in orange, the 
surface exposed DIII lateral ridge epitope (DIII-lr) in cyan, disulphide bridges in 
green, and the carbohydrate side chain (CHO) in grey. (D) Analysis of the 
immunogens used in the study by SDS-PAGE (15%gel) and Coomassie staining. 
Lane 1: Formalin inactivated purified WN virus. Oligomeric bands of C and E are a 
result of protein-crosslinks as a result of formalin treatment. Lane 2: Recombinant 
WN virus sE. Lane 3: Recombinant WN virus DIII. (E) Schematic of the immunization 
schedule with virion (inactivated purified virus), sE, and DIII. With each of these 
antigens, a total of 30 mice (divided into groups of 10) were immunized with 2 doses 
at an interval of 4 weeks. Blood samples were taken 8 weeks after the second 
immunization and the sera of each group of 10 mice were pooled for further 
analyses. (F) Schematic of the immunization schedule for 8 different prime-boost 
regimens. The schedule consisted of two primary immunizations at an interval of four 
weeks followed by two booster immunizations after eight weeks, again at an interval 
of four weeks. For each regimen 10 mice were used. Blood samples were taken eight 
weeks after the second primary immunization as well as two weeks after the second 
booster immunization and pooled for further analyses. 
In panels E and F, black arrows indicate time points of immunization and red arrows 
time points of blood sampling. 
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FIG 2. Serum antibody titers obtained after immunization with virion, sE and DIII. 
(A) Virus neutralization titers (NT90). (B) ELISA titers against different antigens, as 
indicated by the colour codes in the inset. (C) Relative contents of DIII antibodies, 
displayed as the ratio of DIII- versus virion-specific ELISA titers. The data presented 
were derived from the analysis of pooled sera obtained from three groups of ten mice 
per antigen. The figure displays the means of the results obtained with these three 
serum pools. The error bars represent the standard errors of the means. 
 61     
Part I: Publication Journal of Virology 
 
FIG 3. ELISA and NT analysis of virion, sE and DIII post-immunization sera after 
depletion with DIII. (A) Percent DIII-reactive antibodies in post-depletion sera, 
determined by DIII ELISA. (B) Percent virion-reactive antibodies in post-depletion 
sera, determined by virion ELISA. (C) Percent virus neutralizing antibodies in post-
depletion sera, determined by neutralization assay. Results are expressed as percent 
of the titers before depletion. The DIII induced neutralizing antibody titer was <10 
already before depletion (see Fig.2A). The numbers above the bars in A, B, and C 
indicate the calculated percentage of the contribution of DIII antibodies to total 
reactivity. (D) Ratio of DIII-associated neutralizing titers versus DIII-specific ELISA 
titers x100, as a measure of the specific neutralizing activity and thus the functional 
quality of DIII-reactive antibodies. The DIII-associated neutralizing titers were 
deduced from the data in Fig. 2A and 3C and calculated to be 123 and 58 for virion 
and sE sera, respectively.  
*The NT90-titer of DIII-induced antibodies was <10 and therefore no exact ratio 
could be calculated. The error bars represent the standard errors of the means 
obtained in three independent determinations. 
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FIG 4. ELISA analysis of virion, sE, and DIII post-immunization sera after 
depletion with virion. (A) Percent virion-reactive antibodies in post-depletion sera, 
determined by virion ELISA. (B) Percent DIII-reactive antibodies in post-depletion 
sera determined by DIII ELISA. Results are expressed as percent of the titers before 
depletion. The error bars represent the standard errors of the means obtained in 
three independent determinations. 
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FIG. 5. Relative avidities of virion, sE, and DIII post-immunization sera determined 
in virion ELISA +/- urea. The error bars represent the standard errors of the means 
obtained in three independent determinations. 
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FIG 6. ELISA and NT analysis of post-immunization sera using virion or sE for 
priming and DIII for boosting. Panels A to C: Priming (P.) with virion and boosting (B.) 
with DIII. Panels D to F: Priming (P.) with sE and boosting (B.) with DIII. Post-
immunization sera were analyzed in virion ELISA (A and D), DIII-ELISA (B and E) 
and NT (C and F). The error bars represent the standard errors of the means 
obtained in at least three independent determinations. 
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FIG 7. ELISA and NT analysis of post-immunization sera using DIII for priming 
and virion or sE for boosting. Panels A to C: Priming (P.) with DIII and boosting (B.) 
with virion. Panels D to F: Priming (P.) with DIII and boosting (B.) with sE. Post-
immunization sera were analyzed in virion ELISA (A and D), DIII-ELISA (B and E) 
and NT (C and F). 
The error bars represent the standard errors of the means obtained in at least 
three independent determinations. 
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4. Part II: Unpublished Data 
 
4.1 Materials and Methods 
 
 
4.1.1 Production of inactivated TBE and WN viruses 
 
Production of highly purified viruses was carried out essentially as described in 
(39). In brief, primary chicken embryo fibroblasts were infected with WN virus, strain 
NY99 (GenBank# AF196835) or TBE virus strain Neudörfl (GenBank# U27495). The 
cell supernatant was harvested 24 hours p.i., clarified by centrifugation and 
inactivated with formalin (1:2000) for 24 hrs at 37°C. The inactivated virus was 
concentrated by ultracentrifugation and purified by rate zonal followed by equilibrium 
sucrose density gradient centrifugation. 
 
 
4.1.2 Cloning, expression and purification of recombinant soluble E proteins  
 
4.1.2.1 Cloning of recombinant sE 
 
Prior to PCR of prM-sE from TBE virus strain Neudörfl, the Age I restriction site in 
the E protein of the RSP template (2) was mutated by the introduction of a silent point 
mutation (A-G) at position 960 in the E protein nucleotide sequence by site directed 
mutagenesis (invitrogen) using 5`-GCTCCTGTGTTTGGCG CCGGTTTACGCTTC-3` 
and 5`-GCCAAACACAGGAGCACAACAAGAACGGCG-3` as forward and reverse 
primers, respectively. DNA cassettes, encoding prM and soluble, truncated forms 
(first 400 amino acids) of the E proteins (sE) from TBE and WN viruses were 
amplified using the respective RSP templates with the following primers: 
 
TBE sE His: 
• forward: 5’- TTTTAAGAGATCTGCAACGGTGAGGAAAGAAAG-3’ 
• reverse: 5’- ATATAACCGGGTCCGATGCTGCTCCCTTTTTG-3’ 
WN sE: 
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• forward: 5’- AAGAGATCTGGTACCCTCTCTAACTTC-3’ 
• reverse: 5’- ATATAACCGGTTCATCAAGACTTGTGCCAATGGTG-3’ 
WN sE-His: 
• forward:5’- AAGAGATCTGGTACCCTCTCTAACTTC-3’ 
• reverse: 5’- ATATAACCGGTTCATCAAGACTTGTGCCAATGGTG-3’ 
 
The PCR products were subjected to agarose gel electrophoresis, the appropriate 
DNA fragments were purified from the gel, digested using Bgl II and Age I (New 
England Biolabs) restriction enzymes and ligated into the corresponding restriction 
sites of the dephophorylated expression vector pMTBiP/V5-His (Invitrogen) using the 
LigaFast Rapid DNA Ligation System (Promega) according to the manufacturers’ 
protocol. Correct sequences of the inserts in the recombinant DNA plasmids were 
verified by DNA sequencing. 
 
 
4.1.2.2 Stable transfection of S2 cells and expression of recombinant sE 
proteins 
 
Stable transfection of Drosophila Schneider 2 (S2) cells was performed essentially 
as recommended by Invitrogen. Briefly, the recombinant expression plasmids were 
co-transfected with a blasticidin selection plasmid. After transfection, the cells were 
grown in Schneider`s Drosophila medium (Gibco) containing 10% FCS (PAA), 
Penicillin, Streptomycin, Amphotericin B (Invitrogen) and supplemented with 25µg/ml 
blasticidin (Invitrogen) to select for stable transfected cells over a period of two weeks 
and then adapted to protein free medium (Insect Xpress) as recommended by the 
manufacturer (Lonza). 
For the production of the recombinant sE proteins, 1.5*106cells/ml were seeded 
into protein free medium supplemented with 10 µg/ml blasticidin (Invitrogen). Shaking 
cultures were maintained at 100rpm at 28°C and the expression of the recombinant 
sE proteins was induced by adding 500 mM Cu2+. The cell culture supernatant was 
harvested 7 to 11 days post-induction by centrifugation, filtered through a 0.2 µm 
filter (Millipore) and stored at -20°C. 
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4.1.2.3 Purification of recombinant sE proteins 
 
For purification, the cell culture supernatants containing recombinant sE proteins 
from TBE and WN viruses, were subjected to immunoaffinity chromatography using 
the broadly flavivirus cross-reactive mouse monoclonal antibody 4G2 (ATCC# HB- 
112), which was coupled to a sepharose column via N-hydroxysuccinimide chemistry 
(GE healthcare). The bound recombinant proteins were eluted by 20 mM glycine, pH 
2.5. Peak fractions were back-neutralized immediately to pH 8.0 with 2 M Tris-Cl pH 
9.5, buffer exchanged to TAN buffer (0,05 M triethanolamin 0,1 M NaCl, pH 8.0) by 
ultrafiltration and stored at -80°C. 
 
 
4.1.3 Cloning, expression and purification of recombinant DIII proteins 
 
4.1.3.1 Cloning of recombinant DIII 
 
DNA fragments encoding TBE virus (strain Neudörfl) E protein amino acids 302-
394 and WN virus (strain NY99) E protein amino acids 300-399 were amplified by 
PCR from the respective RSP clones as templates (2), using HFII polymerase 
(Clontech) using the following primers: 
 
TBE DIII: 
• Forward: 5`- GGTATTGAGGGTCGCCTTACGTACACAATGTGT-3` 
• Reverse: 5`-AGAGGAGAGTTAGAGCCTCATCATTGGAACCATTGATGACT-3` 
TBE DIII-His: 
• Forward: 5`-GGTATTGAGGGTCGCCTTACGTACACAATGTGT-3` 
• Reverse:5`-AGAGGAGAGTTAGAGCCTCATCAGTGGTGGTGGTGGTGGT 
      GTTGGAACCATTGATGACTC-3` 
WNV DIII: 
• forward 5`-GGTATTGAGGGTCGCACAACCTATGGCGTCTGTTC-3` 
• reverse: 5`-AGAGGAGAGTTACCTCATCACTTGTGCCAATGGTGATTG-3` 
WNV DIII-His  
• Forward: 5`-GGTATTGAGGGTCGCACAACCTATGGCGTCTGTTC-3` 
• reverse:5`-AGAGGATTAGAGCCTCATCAGTTGTTGTTGTTGTTGTGCTT 
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    GTGCCAATGGTGATGG-3` 
 
The PCR products were subjected to agarose gel electrophoresis, the appropriate 
DNA fragments were purified from the gel, treated with T4 DNA polymerase as 
recommended by Novagen and cloned into the pET 32a Xa/LIC expression vector by 
ligation independent cloning, according to the manufacturer’s instructions (Novagen). 
Correct sequences of the clones were verified by DNA sequencing. In the case of the 
vector encoding the DIII-His fusion proteins, the DNA sequences encoding the N-
terminal His-tag were deleted by site-directed mutagenesis (Invitrogen) and the 
correct sequences were verified by DNA sequencing (Fig 4.1). 
 
 
4.1.3.2 Expression of DIII-thioredoxin fusionproteins in E.coli 
 
The recombinant DIII expression plasmids were transformed into E.coli strain 
BL21 (Novagen). 500ml of fresh Luria Broth medium, supplemented with 100µg/ml 
ampicillin (Sigma), were inoculated with 20ml of an over night culture (o/n) and grown 
at 37°C until the OD600 reached 0.5-0.6. Expression of the fusion proteins was 
induced by the addition of Isopropyl-ß-D thiogalactopyranoside (IPTG, Sigma) to a 
final concentration of 0.5 mM for 4h at 30°C. The cells were harvested by 
centrifugation at 16,000g for 10 minutes at 4°C, lysed with Bug Buster Protein 
Extraction Reagent (Novagen) and the lysate was centrifuged at 16,000g at 4°C for 
30 min. The supernatant was filtered through a 0.2µm filter and used for purification 
of DIII. 
 
 
4.1.3.3 Purification of recombinant DIII proteins 
 
The supernatant of the lysate of DIII producing bacteria was applied onto chelating 
sepharose columns (GE Healthcare) loaded with Ni2+. The column was washed with 
buffer containing 20mM imidazole equilibrated with factor Xa cleavage buffer and 
thioredoxin was cleaved off by proteolytic cleavage over night at room temperature 
with 90U/ml of factor Xa (Novagen). After cleavage, DIII proteins (used as 
immunogens in mice) were eluted from the column by washing with buffer, leaving 
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the thioredoxin fusion partner bound to the column (Fig. 4.1A). In the case of DIII-His 
used for immunological assays, the thioredoxin fusion partner was cleaved off from 
DIII-His by factor Xa and eluted with wash buffer, while the DIII-His protein remained 
bound to the column. DIII-His was then eluted by a linear imidazole gradient (0-
500mM imidazole) (Fig. 4.1B). 
The DIII-protein containing solution was buffer exchanged to 20mM triethanolamin, 
pH 8.0, by ultra-filtration (MWCO=3000Da, Sartorius), applied onto Sepharose Q 
anion exchange chromatography columns (GE healthcare Life Sciences), and eluted 
by a continuous salt gradient (0-1M NaCl). The DIII preparations were buffer 
exchanged to TAN, pH 8.0, using ultrafiltration and stored at -80°C. 
 
 
4.1.4 Protein quantification assay 
 
The concentrations of purified recombinant proteins were determined by BCA 
(bicinchoninic acid) protein assay (Pierce) according to the manufacturer’s 
instructions. 
 
 
4.1.5 S-alkylation of recombinant DIII and sE proteins 
 
Purified recombinant sE and DIII proteins in TAN pH 8.0 were reduced with 
100mM dithiothreitol (DTT) in the presence of 2% SDS, for 1h at 65°C. Free -SH 
groups in the cysteines were alklyated (S-alkylation) by incubation with 300mM 
iodoacetic acid (dissolved in 1M NaOH acid, pH 8.0) for 30min at room temperature. 
The reaction was stopped by adding DTT. The buffer was exchanged to TAN, pH 8.0, 
using PD-10 desalting columns (GE Healthcare). 
 
 
4.1.6 Western blot analysis 
 
100 ng of purified recombinant proteins were subjected to 15% SDS-PAGE 
according to Laemmli (52). The polyvinyldifluoride (PVDF, BioRad) membrane was 
soaked in methanol (Merck) and then equilibrated together with the gel and the 
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blotting paper in blotting buffer (48 mM Tris, 39 mM Glycine, 1.3 mM SDS, 20% 
methanol). The protein was transferred for 90min at 15V onto the PVDF membrane in 
a semidry blotting apparatus (Bio Rad). The membrane was blocked with 1% bovine 
serum albumin (BSA) in PBS + 0.1% Tween 20 over night at 4°C. The primary 
antibody, diluted in blocking solution, was added for 2h at RT. The membrane was 
washed with distilled H2O and incubated with the peroxidase labelled IgG-specific 
secondary antibody for 90 minutes at RT. The substrate reaction was carried out 
using Sigma Fast DAB Urea/H2O2 tablets (Sigma) dissolved in H2O+ 10% Ni2+. 
 
 
4.1.7 Mass spectrometry 
 
Mass spectrometry (MS) analyses were performed at TOPLAB GmbH, Martinsried 
Germany. Briefly, recombinant DIII proteins from TBE and WN viruses were alkylated 
and proteolytically digested under reducing and non-reducing conditions. The peptide 
fragments were subjected to Matrix-assisted laser desorption/ionization (MALDI) and 
Time of Flight (TOF) mass spectrometric analyses and disulfide bridged peptides 
were identified according to their molecular mass. 
 
 
4.1.8 Chemical cross-linking of recombinant sE proteins 
 
Purified recombinant soluble E proteins in TAN pH 8.0 were incubated with 10mM 
dimethylsuberimidate (DMS) for 30 minutes at room temperature, precipitated with 
trichloroacetic acid and analyzed by SDS-polyacrylamide gel electrophoresis. 
 
 
4.1.9 Sedimentation analyses 
 
5µg of purified recombinant sEs and sE dimers isolated from infectious TBE 
virions (79) were applied to 7-20% (wt/wt) continuous sucrose gradients in TAN 
buffer, pH 8.0, or 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 6.0, 
containing 0.1% Triton X-100 and centrifuged for 20h at 38,000 rpm at 15°C in a 
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Beckman SW40 rotor. After centrifugation, the gradient was fractionated and the 
fractions were used for further analyses. 
 
 
4.1.10 Quantitative sE protein-specific SDS-ELISA 
 
Microtiter plates (Nunc, Roskilde, Denmark) were coated with TBE virus-specific 
serum (raised in guinea pigs) or purified broadly cross-reactive mab 4G2 in 
carbonate buffer, pH 9.6, over night at 4°C for the catching of TBE or WN virus sEs, 
respectively. Samples (cell culture supernatants of stably transfected and induced S2 
cells or purified sEs) were incubated in the presence of 0.4% SDS for 30 min at 
65°C. Dilutions of the samples in ELISA buffer (PBS pH 7.4, 2% Tween-20, 2% lamb 
serum) were then added to the plates and incubated for 90 minutes at 37°C. The 
plates were washed, incubated with TBE or WN virus-specific polyclonal rabbit sera 
for 1h at 37°C, washed again and incubated with peroxidase labelled anti-rabbit IgG 
antibody for another 1h at 37°C. For the detection of the bound enzyme conjugate, o-
phenylenediamine dihydrochloride (OPD, Sigma) was added and the reaction was 
stopped with 2N H2SO4. The absorbance was measured at 490 nm. Calculation of 
protein concentrations in the samples was performed using a standard curve with the 
appropriate purified sE. 
 
 
4.1.11 Mouse immunization experiments 
 
(A) Dose finding using sE and DIII from TBE virus 
Groups of four female 6 to 8 weeks old C57BL/6 mice (Charles River Laboratories, 
Kisslegg, Germany) were immunized sub-cutaneously with 1, 5 or 20 µg of soluble E 
purified from infectious TBE virions (79) or purified recombinant TBE DIII, each 
adsorbed to 0.2% Al(OH)3 (Aluminum hydroxide gel, Sigma) in 100µl TAN buffer, pH 
8.0. Mice were immunized three times at an interval of two weeks and blood samples 
were withdrawn using microvette 200 capillaries (Sarstedt) before each of the 
immunizations and two weeks after the third. The serum samples of each group were 
pooled for further analyses. 
(B) Sequential prime-boost immunizations using WN virus antigens 
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Six to eight weeks old C57BL/6 mice (Charles River Laboratories) were 
immunized sub-cutaneously with inactivated whole virus (1µg), sE (5µg) or DIII 
(20µg) in 100µl TAN, of West Nile virus as described in the manuscript. 
 
 
4.1.12 Virion ELISA 
 
The virion ELISAs were carried out as described in the manuscript. For the 
analysis of sera from the dose-finding experiment, whole inactivated TBE virus was 
used as an antigen. 
 
 
4.1.13 Blocking ELISA 
 
Three-fold serial dilution of the recombinant TBE virus sE-His and sE isolated from 
infectious TBE virions (79) were incubated with a predefined concentration of 
monoclonal antibodies (mabs) for 90 minutes at 37°C. Mabs which were not blocked 
by sE were then detected by virion ELISA using TBE virus as antigen. 
 
 
4.1.14 sE and DIII ELISAs: 
 
Maxisorp microtiter plates (Nunc, Roskilde, Denmark) were coated with rabbit anti 
His-tag IgG antibody (QED Bioscience) in carbonate buffer, pH 9.6, over night at 4°C. 
Recombinant DIII-His or sE-His proteins of TBE and WN viruses were added at a 
concentration of 1 and 0.5µg/ml respectively, for 1h at 37°C. Three-fold serial 
dilutions (starting at 1:100) of polyclonal mouse sera were then added for 1h at 37°C. 
As negative controls, sera from naïve mice were included and used for cut-off 
determination. The bound antibodies were detected using peroxidase labelled goat 
anti-mouse immunoglobulin G (Pierce) for 1h at 37°C. Titration curves were 
established using Graph pad Prism 5 software and serum titers were defined at an 
absorbance of 490 nm and a cut-off of 0.35, as deduced from the analysis of 
negative control sera, 
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4.1.15 TBE and WN virus neutralization assays 
 
TBE virus neutralization assay was carried out essentially as described in (94). In 
brief, twofold serial dilutions of mouse sera, starting at 1:10, were mixed with 25 
plaque-forming units (pfu) of TBE virus incubated for 1h at 37°C, added to a BHK cell 
monolayer and incubated for three days at 37°C. The presence of virus in the 
supernatant was determined by a four-layer SDS-ELISA. The titer was defined as the 
reciprocal of the serum dilution resulting in a 50% reduction of in the absorbance in 
ELISA (NT50). 
The WN virus neutralization assay was carried out on Vero cells (ECACC 
#84113001) using WN strain NY99 as described in the manuscript. 
 
 
4.1.16 Antibody depletion assay 
 
Antibody depletion assays were performed as described in the manuscript. 
Recombinant TBE virus sE-His was used as an antigen for the depletion of broadly 
cross-reactive antibodies and DIII-His of TBE and WN viruses for the depletion of 
DIII-reactive antibodies.  
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4.2 Results 
 
 
4.2.1 Production and characterisation of recombinant proteins of WN and TBE 
viruses 
 
The goal of this part of the thesis was the production of highly pure and properly 
folded recombinant proteins for the use as immunogens in mice and as antigens in 
immunological assays for analyzing the mouse post-immunization sera. The following 
section describes the production and characterization of recombinant soluble, 
truncated E proteins (sE) and domain III (DIII) of the E protein both with and without a 
C-terminal His-tag, to be used for assays and for immunization, respectively. The 
immunization study was conducted with WN virus antigens and TBE virus antigens 
were used as controls. 
 
 
4.2.1.1 Cloning, expression, purification and characterization of recombinant 
DIIIs 
 
Studies with several flaviviruses had shown that properly folded DIII can be 
expressed in bacteria in high amounts (6, 69, 80, 102, 103). Therefore, a high-yield 
bacterial expression system (E.coli) was chosen for the production of recombinant 
DIII proteins. To promote the formation of the single disulfide bridge and to increase 
solubility, DIII was expressed as a fusion protein with thioredoxin (trx) (Fig. 4.1). In 
addition, the fusion protein contained a His-tag for affinity purification and a 
proteolytic cleavage site for the separation of DIII from the fusion partner (Fig. 4.1). 
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4.2.1.1.1 Cloning of DIII  
 
For the production of DIII with and without a His-tag, two different cloning 
strategies were necessary (Fig. 4.1). The expression vector encoded two His-tags. 
One was located in the N-terminal part of the fusion protein which was cleaved off 
during the purification of the DIII proteins, and a second was located at the C-
terminus, separated from the cloning site by a linker sequence (Fig. 4.1). 
For the production of DIII without a His-tag, the C-terminal His-tag and the linker 
between the His-tag and the DIII insert had to be removed. This was accomplished 
by introducing a stop codon by PCR after the last DIII codon of the DIII insert (Fig. 
4.1A). 
For the production of His-tagged DIII two obstacles had to be overcome. First, the 
C-terminal vector-encoded His-tag was separated from the cloning site via a linker 
(indicated by a black bar in Fig 4.1B). To avoid the possibility of any cross reactivities 
of this linker in subsequent immunological assays, it was removed by the use of PCR 
primers, which were designed to introduce a His-tag followed by a stop codon 
immediately after the last DIII codon (Fig. 4.1B). Secondly, the N-terminal His-tag, 
next to the thioredoxin fusion partner, had to be removed, because the presence of 
both His-tags would cause problems during the Ni2+-affinity purification of the DIII-His 
protein. Therefore the internal His-tag was removed by site directed mutagenesis 
after the DIII-His DNA fragment was cloned into the expression vector (Fig. 4.1B). 
Correct sequences of the recombinant DIII constructs were verified by DNA 
sequencing. 
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Fig. 4.1 Strategy for the cloning, expression and purification of recombinant DIII proteins. 
(A) Cloning, expression and purification of DIII proteins used as immunogens in mice 
(B) Cloning, expression and purification of DIII-His proteins used as antigens in immunological assays. 
DIII is colored in blue, stop codons (Stop) in red, His-tags in green, the thioredoxin fusion partner (trx) 
in brown, the proteolytic cleavage site (Xa) in yellow and linker sequences in black. 
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4.2.1.1.2 Expression of the trx-DIII fusion proteins in E.coli 
 
For the expression of the fusion proteins, E.coli bacteria were transformed with the 
recombinant plasmids and expression was induced with IPTG. To analyze the 
expression of the fusion protein in the soluble and insoluble cell fractions, bacteria 
were harvested by centrifugation, lysed with detergent and the lysate was subjected 
to centrifugation at 10,000g for 10 minutes. Aliquots from the pellet (insoluble 
fraction), the supernatant (soluble fraction) as well as cells before lysis (total cellular 
protein) were subjected to SDS-PAGE and densitometric analysis to determine the 
distribution of the expressed fusion protein in the soluble and insoluble material. As 
shown in Fig.4.2 the fusion protein is present in the soluble as well as in the insoluble 
fraction, at a ratio of ~1:10, as determined by densitometric analysis. 
 
 
Fig. 4.2 SDS-PAGE and Coomassie staining of different cellular fractions of E.coli expressing 
trx-DIII fusion proteins. 
Aliquots of total cellular protein (TCP), the soluble (sol) and the insoluble phase (inclusion bodies, IB) 
of cells expressing the trx-DIII fusion proteins of TBE and WN viruses were subjected to SDS-PAGE 
and Coomassie staining. The position of the trx-DIII fusion protein is indicated by an arrow. The 
soluble phase of E.coli not expressing the fusion protein (BL21) was used as a negative control. M: 
molecular weight markers. 
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4.2.1.1.3 Purification of recombinant DIII 
 
Although most of the recombinant protein was found in the insoluble fraction, DIII 
was purified from the soluble fraction to avoid solubilisation of the protein from 
insoluble inclusion bodies with chaotropic reagents and the refolding of the denatured 
proteins. For purification, the soluble fraction of the bacterial lysate was applied onto 
a Ni2+ loaded column to bind the recombinant fusion proteins via the His-tag as 
indicated in Fig.4.1. As revealed by SDS-PAGE and densitometric analyses of the 
soluble phase and the column flow through, the fusion proteins bound almost 
quantitatively to the column (Fig 4.3C). The bound fusion proteins were proteolytically 
cleaved on the column by incubation with factor Xa. DIII without a His-tag was then 
eluted by a washing step while the fusion partner remained associated with the 
column via the internal His-tag (Fig. 4.1A). In contrast, His-tagged DIII remained 
bound to the column after Xa cleavage, and the cleaved-off thioredoxin fusion partner 
was removed by a washing step. DIII-His was then specifically eluted by an imidazole 
gradient (Fig. 4.1B). To determine recovery and purity, the eluted DIII preparations 
were subjected to SDS-PAGE and densitometric analyses of the stained protein 
bands. The recovery of the DIII proteins after the proteolytic digest was between 60 
to 80% relative to the starting material (soluble fraction) (Fig. 4.3C). The obtained DIII 
proteins were insufficiently pure (see also sample in lane 4 of the SDS-PAGE 
analysis of a representative purification procedure of WN virus DIII-His) (Fig. 4.3A). 
To increase purity, the DIII proteins were subjected to a further round of purification 
using anion exchange chromatography. As shown in Fig. 4.3A and B, the purified DIII 
proteins migrated as single bands in SDS-gels and the recovery was between 40 to 
55% (Fig. 4.3C). 
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Fig. 4.3 Characterisation of the DIII purification process. 
(A) SDS-PAGE and Coomassie staining of aliquots from successive steps of a representative DIII 
purification procedure (WN virus DIII-His). M = molecular weight marker; lane 1: soluble fraction of 
E.coli cells not expressing the thioredoxin-DIII fusion protein; lane 2: soluble fraction of E.coli 
expressing the thioredoxin-DIII fusion protein, indicated by a red rectangle; lane 3: Ni2+ column flow-
through; lane 4: pool of eluted fractions after on-column proteolytic digest with factor Xa; lane 5: pool 
of elution fractions subjected to anion exchange chromatography (AEC) lane 6: AEC column wash 
after application; lane 7: pool of eluted DIII containing fractions from the AEC column; 
(B) SDS-PAGE and Coomassie staining of purified TBE virus DIII, TBE virus DIII-His, and WN virus 
DIII proteins. 
(C) Yield after successive purification steps, relative to the total amount of DIII in the starting material. 
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4.2.1.1.4 Characterization of the purified recombinant DIII proteins 
 
The formation of the single disulfide bridge has been shown to be critical for 
proper folding of DIII (84). To asses the presence of the disulfide bond of purified DIII 
proteins, we first analyzed their migration behaviour by SDS-PAGE under reducing 
and non-reducing conditions. As a control, S-alkylated DIII was also included in the 
analysis (Fig. 4.4). For that purpose DIII was reduced and free –SH residues were 
chemically modified by the addition of an alkylating agent to avoid spontaneous 
reformation of the disulfide bridge (see Materials and Methods). As shown in figure 
4.4A, TBE virus DIII protein exhibited a migration difference upon reduction and S-
alkylation compared to the non-reduced sample, which is consistent with the 
presence of the disulphide bridge in this preparation. In contrast, using the TBE virus 
DIII as a control, WN virus DIII proteins did not show such a migratory difference 
upon reduction or S-alkylation (Fig. 4.4 B, C). 
As a further test for proper folding, we employed a Western blot assay, under non-
reducing conditions, using equal amounts of purified non-treated and S-alkylated 
DIIIs and conformation dependent DIII-specific monoclonal antibodies (mabs). These 
mabs lose reactivity upon reduction. As positive controls, TBE and WN virus specific 
polyclonal immune sera were used. As shown in Fig. 4.5, the polyclonal sera (KVIII, 
TBE virus-specific; KIS2, WN virus-specific) reacted both with the non-reduced as 
well as with the S-alkylated DIII proteins. In contrast, the conformation-dependent 
mabs B4 (TBE virus DIII-specific; (32)) and E16 (WN virus DIII-specific; (70)) reacted 
with the respective DIIIs under non-reducing conditions only, consistent with the 
presence of the disulfide bridge in these preparations. 
In addition to the biochemical and immunological characterizations described 
above, mass spectrometry analyses were carried out to provide direct evidence for 
the presence of the disulphide bridge in the purified DIII preparations. The analysis 
was performed by a commercial protein analysis service (Toplab, Martinsried, 
Germany). After proteolytic digestion under reducing and non-reducing conditions, 
the resulting peptide fragments were analyzed by matrix-assisted-laser-
desorption/ionization (MALDI) combined with time-of-flight (TOF) analysis. For all 
DIIIs analyzed, peptide fragments having a molecular mass corresponding to a 
disulfide bridged linear di-peptide were identified under non-reducing conditions. 
These were separated into two linear peptides of a distinct mass upon reduction, 
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providing direct evidence for the presence of the disulfide bridge in all DIII 
preparations (data not shown).  
Taken together, these results suggest that the recombinant DIII proteins were 
obtained in a proper conformation. 
 
 
Fig. 4.4 SDS-PAGE and Coomassie staining of purified untreated and S-alkylated DIIIs under 
reducing and non-reducing conditions 
(A) TBE virus DIII 
(B) WN virus DIII 
(C) WN virus DIII-His 
In panels B and C, lanes 2-4 represent the TBE virus DIII as a control. M: molecular weight markers.  
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Fig. 4.5 Western blot of purified DIIIs under non-reducing conditions 
Untreated and S-alkylated recombinant DIII proteins were subjected to SDS-PAGE and Western 
blotting under non-reducing conditions. Immunodetection was carried out with TBE (KVIII) and WN 
virus (KIS 2) -specific polyclonal sera (positive controls) and conformation-sensitive mabs B4 (TBE 
virus DIII-specific) and E16 (WN virus DIII-specific). 
 
 
4.2.1.2 Cloning, expression, purification and characterization of recombinant 
sE proteins  
 
The goal of this part of the thesis was to produce large amounts of highly pure and 
properly folded soluble, truncated forms of the envelope glycoprotein E (sE) of TBE 
and WN viruses using the Drosophila expression system. Analogous to the 
production of DIII, sE proteins were produced without a His-tag for immunization of 
mice and with a His-tag for the use as antigens in immunological assays.  
 
 
4.2.1.2.1 Cloning of recombinant sE  
 
As shown in Fig. 4.6, the expression vector encodes a drosophila-specific BIP 
signal sequence, which is necessary for targeting the proteins into the secretory 
pathway and their export into the cell culture supernatant, a so-called V5 epitope and 
a C-terminal His-tag. The V5 epitope is a 14 amino acid long tag which is not 
required for our study. Therefore, the Bgl II and Age I restriction sites were used for 
cloning, thus excising the DNA sequence coding for the V5 epitope (Fig. 4.6). PrM is 
believed to serve as a chaperone for the correct folding of E (62). Therefore, prM-sE 
encoding expression cassettes were amplified using RSP clones encoding the full-
length prM and E proteins of the respective viruses (2) (Fig. 4.6) as templates. The E 
protein encoded by the TBE virus RSP construct contained an Age I restriction site 
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which was removed by the introduction of a silent mutation by site-directed 
mutagenesis, prior to amplification of the prM-sE cassette. Successful mutation was 
confirmed by DNA sequencing. 
To generate sE without a His-tag for immunisation and with a His-tag for the use 
as an antigen in immunological assays, two different cloning strategies were 
employed, as indicated in Fig. 4.6. To clone sE without a His-tag, a stop codon was 
introduced by PCR immediately after the last codon of sE (Fig. 4.6A). To generate sE 
with a His-tag the prM-sE fragment was cloned in-frame with the vector-encoded His-
tag (Fig. 4.6B). The amplified inserts were gel purified, treated with Bgl II and Age I 
restriction enzymes and cloned into the corresponding sites of the expression vector. 
Successful cloning and correct sequences were verified by DNA sequencing. 
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Fig. 4.6 Strategy for the cloning, expression, and purification of recombinant sE proteins 
(A) Cloning, expression, and purification of sE proteins used as immunogens in mice 
(B) Cloning, expression, and purification of sE-His proteins used as antigens in immunological assays. 
Soluble E (sE) is colored in orange, prM in pink, the BIP signal sequence in purple, the V5 epitope in 
blue, stop-codons (Stop) in red, His-tags in green, restriction sites and the amino acids (TG=threonine, 
glycine; RS=arginine, serine) they encode in grey. 
 
 
4.2.1.2.2 Generation of stably transfected cell lines  
 
To generate cell lines for the continuous expression of recombinant protein, the 
recombinant expression plasmids were co-transfected together with a blasticidin 
resistance-encoding plasmid into Schneider 2 (S2) Drosophila cells. Blasticidin 
selection was applied for two weeks to obtain stably transfected cells. Expression 
was induced by the addition of Cu2+. To test for successful secretion of recombinant 
protein into the medium, aliquots of the cell culture supernatant from induced cells 
were analyzed by E protein-specific quantitative ELISA (data not shown).  
 
 
4.2.1.2.3 Expression and purification of the recombinant sE proteins 
 
For the expression of recombinant sE proteins, stably transfected cells were 
induced by the addition of Cu2+ to the culture medium and the cell culture 
supernatant was harvested by centrifugation 7 to 11 days post induction. The 
recombinant sE proteins were purified from the cell culture supernantant by 
immunoaffinity chromatography using the purified broadly flavivirus cross-reactive 
monoclonal antibody 4G2. As determined by SDS-ELISA, this procedure allowed the 
recovery of 60 to 70% of the sE from the starting material. To asses the purity, the 
eluted and buffer-exchanged proteins were subjected to SDS-PAGE and 
densitometric analysis. As shown in Fig. 4.7, the recombinant proteins had a purity of 
at least 90%. 
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Fig. 4.7 SDS-PAGE and Coomassie staining of purified recombinant sE proteins 
The lanes of the WN sE, sE-His and TBE sE-His proteins are indicated. M: molecular weight markers. 
 
 
4.2.1.2.4 Assessment of the oligomeric structure of the recombinant sE 
proteins 
 
To analyze the oligomeric state of the purified sE proteins, a chemical cross-
linking experiment was performed using dimethylsuberimidate (DMS) and sE dimers 
obtained from infectious TBE virions (vTBEV sE) as controls (79). As shown in 
Fig.4.8, both recombinant TBE virus sE-His and the dimer control (vTBEV sE) 
showed two bands corresponding to an E dimer confirming the dimeric nature of the 
recombinant TBE virus sE protein. In contrast, WNV sE and sE-His migrated as 
monomers. Only a faint band at the molecular weight of a dimer was present 
indicating that either the recombinant sEs of WN virus are predominantly monomers 
or that they cannot be cross-linked with DMS. 
For further investigation of their oligomeric state, the recombinant sE proteins were 
subjected to sucrose density gradient analysis at alkaline (pH 8.0) and acidic pH (pH 
6.0). In general, E protein dimers are stable at pH 8.0, but dissociate into monomers 
upon acidification, both having different migration behaviours in sucrose density 
gradients. The recombinant sE proteins and, as a control, the sE dimers from 
infectious TBE virions (vTBEV sE), were pre-incubated at pH 6.0 or pH 8.0, applied 
onto sucrose density gradients with respective pH and subjected to ultra-
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centrifugation. After centrifugation the gradient was fractionated and the distribution 
of the sE proteins in the fractions was analyzed by quantitative E protein-specific 
SDS-ELISA (Fig. 4.9). As expected, TBE sE from infectious virions sedimented as 
dimers at pH 8.0 and monomers at pH 6.0 (Fig. 4.9A, B, C). Recombinant TBE virus 
sE-His (Fig. 4.9A) showed the same sedimentation behaviour as the viral sE dimer, 
confirming the result of the chemical cross-linking experiment. The WN virus sE 
proteins (Fig. 4.9 B, C) in contrast, sedimented as monomers both at pH 6.0 and pH 
8.0, again consistent with the cross-linking experiment. 
These data indicate that the recombinant TBE virus sE-His protein was a dimer, 
whereas the sE and sE-His of WN virus formed predominantly monomers. 
 
 
 
Fig. 4.8 SDS-PAGE and Coomassie staining of DMS-treated recombinant sE proteins. 
The lanes of the vTBEV sE (control) and the recombinant sEs, the molecular weight markers (M) and 
the positions of the monomer and dimer are indicated. 
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Fig. 4.9 Sedimentation analyses of recombinant sE proteins. 
Distribution of the recombinant sE proteins (indicated by the colour code in the inset) in the sucrose 
density gradient (pH 8.0 and 6.0) as determined by SDS-ELISA. In all panels, the sE isolated from 
infectious TBE virions (vTBE sE) was used as a control. Positions of the monomer (M) and dimer (D) 
are indicated by an arrow. 
(A) Recombinant TBEV sE-His 
(B) Recombinant WNV sE 
(C) Recombinant WNV sE-His 
 
 
4.2.1.2.5 Evidence for proper folding of purified recombinant sE proteins 
 
To analyze proper folding, recombinant sEs were subjected to an analysis with 
conformation sensitive mabs using Western blotting under non-reducing conditions. 
For this assay, non-treated and S-alkylated sEs were incubated with polyclonal 
control sera, DIII-specific and broadly cross-reactive conformation sensitive mabs, 
which only react when the disulfide bridges are properly formed. Fig. 4.10 shows 
Western blots with a representative set of mabs. The S-alkylated and untreated sEs 
reacted with the polyclonal control sera (TBE virus-specific, KVIII; WN virus-specific, 
KIS2), but the monoclonal antibodies (TBE virus specific A1 (DII), B3, B4 (DIII), (32); 
WN virus specific E16, E24 (DIII), (70)) reacted only with the non-treated but not with 
the S-alkylated forms. This is an indication for the proper formation of the disulfide 
bridges suggesting that the sE proteins had a correct conformation. 
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To compare the overall fold of the recombinant TBE virus sE-His with that of the 
sE isolated from infectious TBE virions (vTBEV sE), a blocking ELISA with 
conformation-dependent monoclonal antibodies was carried out. Figure 4.11 shows 
for DI (IC3), DII (A3) and DIII (B4) -specific monoclonal antibodies that the blocking 
pattern is identical for recombinant and viral sE, which is consistent with proper 
folding of the recombinant sE protein. 
To summarize, the chosen cloning, expression and purification strategy led to the 
successful production of high amounts of at least 90% pure recombinant sE proteins 
in a correct conformation. 
 
 
 
 
Fig. 4.10 Western blot analyses of untreated and S-alkylated purified sEs. 
The sEs were subjected to SDS-PAGE and Western blotting under non-reducing conditions. 
Immunodetection was carried out with polyclonal TBE (KVIII) and WN (KIS2) virus-specific rabbit sera 
and the conformation-dependent mabs A1 (broadly cross-reactive), B3, B4 (TBE virus DIII-specific) 
and E16, E24 (WN virus DIII-specific) (70). 
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Fig. 4.11 Blocking ELISA with mabs, recombinant TBE sE-His and TBE sE isolated from 
infectious virions. 
Titration curves of mabs IC3 (DI-specific), A3 (DII-specific), and B4 (DIII-specific) in TBE virion ELISA 
after pre-incubation with recombinant TBE sE-His (red curves) and TBE sE obtained from infectious 
virions (79) (vTBE sE, blue curves). The error bars represent the standard error of the means obtained 
in three independent determinations. 
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4.2.2 Dose-finding immunisation experiment in mice 
 
It was the primary goal of this thesis to assess the induction of neutralizing 
antibodies by different WN virus antigens in different prime boost regimens. Since the 
specific immunogenicity of different physical forms of the antigen can be different 
(37), a dose finding experiment in mice had to be conducted. 
The conditions for the induction of a neutralizing antibody response using whole 
inactivated virus as an immunogen in mice was already established by previous 
studies conducted in our group (data not shown). Therefore, the dose finding 
experiment was performed with purified DIII and sE. At this stage of the project, 
recombinant WN virus antigens were not yet available. For this reason, the already 
purified recombinant TBE virus DIII and the sE isolated from infectious TBE virions 
(79) were used as analogues for mouse immunizations. Groups of 6-8 week old 
female C57/BL6 mice (4 mice per group) were immunized three times at an interval 
of two weeks with 1, 5 or 20µg of DIII and sE, with and without aluminium hydroxide 
(Al(OH)3), subcutaneously into the skin at the neck. Blood samples were taken before 
each of the immunizations and 14 days after the third and the sera of each group 
were pooled. The serum pools were analyzed by TBE virus specific IgM and IgG 
ELISAs and the functional activity was determined by TBE virus neutralization 
assays. 
 
 
4.2.2.1 Analyses of DIII post-immunization sera  
 
Groups which received recombinant DIII without aluminium hydroxide did not show 
any reactivity in the TBE virus specific IgM and IgG ELISA indicating that soluble DIII 
alone was not sufficiently immunogenic under the conditions used (data not shown). 
In contrast, DIII adsorbed to aluminium hydroxide induced a TBE virus specific IgM 
and IgG antibody response (Fig. 4.12A and B, respectively). IgM titers in groups 
receiving 1µg of DIII were below the detection limit even after the third immunization 
(Fig. 4.12A). The induction of IgG antibodies was clearly dose-dependent (Fig. 
4.12B) and neutralizing antibody titers (NT50) were only detectable after immunization 
with two or three doses of 20µg (Fig. 4.12C). 
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4.2.2.2 Analyses of sE post-immunization sera  
 
sE obtained from infectious virus induced a specific IgM and IgG antibody 
response with and without the use of aluminium hydroxide as an adjuvant (Fig 4.13 
A-D). IgM (Fig. 4.13A, B), IgG (Fig. 4.13C, D) and neutralizing antibodies (NT50) (Fig. 
4.13E, F) were detected in all samples at least after two doses. In the group receiving 
sE+aluminium hydroxide, IgM antibodies were measured already after a single dose 
(Fig. 4.13B) in contrast to mice receiving sE only, which were tested positive for IgM 
after the second dose (Fig. 4.13A). Highest IgG titers were detected in groups 
receiving three doses and appeared to be slightly higher in groups receiving adjuvant 
(Fig. 4.13D). As shown in Fig. 4.13 E and F, neutralizing antibodies (NT50) were 
induced by all doses (+/- aluminium hydroxide), at least after two immunizations. 
 
 
4.2.2.3 Conclusions 
 
The dose-finding experiment provided an excellent basis for the selection of the 
amounts of antigens to be used in sequential and prime-boost immunization studies. 
DIII was the weakest immunogen and required a dose of 20µg (+ aluminium 
hydroxide), followed by sE (5µg) and inactivated virion (1µg), as determined in 
previous analyses. 
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Fig. 4.12 Analyses of TBE virus DIII post-immunization sera by TBE virus specific ELISAs and 
neutralization assays. 
(A) TBE virus-specific IgM ELISA titers. 
(B) TBE virus-specific IgG ELISA titers. 
(C) TBE virus-specific neutralization titers (NT50). 
In all panels, the dose of the immunogens in µg and the number of immunizations are indicated on the 
x-axis. Serum pools from mice receiving 1, 5, or 20µg are indicated in red, green and orange bars, 
respectively. The error bars represent the standard errors of the means obtained in two independent 
determinations. 
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Fig. 4.13 Analyses of TBE virus sE post-immunization sera by TBE virus specific ELISAs and 
neutralization assays. 
(A, B) TBE virus-specific IgM ELISA titers in sE (A) and sE+Al(OH)3 (B) post-immunization sera. 
(C, D) TBE virus-specific IgG ELISA titers in sE (C) and sE+Al(OH)3 (D) post-immunization sera. 
(E, F) TBE virus-specific neutralization titers (NT50) in sE (E) and sE+Al(OH)3 (F) post-immunization 
sera. 
In all panels, the dose of the immunogens in µg and the number of immunizations are indicated on the 
x-axis. Serum pools from mice receiving 1, 5, and 20µg are indicated by red green and orange bars, 
respectively. The error bars represent the standard errors of the means obtained in two independent 
determinations. 
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4.2.3 Development of immunological assays 
 
The goal of this part of the thesis was to establish assay formats that allowed the 
analysis of the fine-specificity of the polyclonal antibody response in mice after 
immunization with WN virus antigens (inactivated virion, recombinant sE and DIII). To 
determine serum antibody titers, ELISAs employing different antigens were 
established. To quantify the contribution of a specific subset of antibodies to the 
neutralizing antibody response, serum depletion assays were developed. 
 
 
4.2.3.1 Development of a DIII ELISA format 
 
For the determination of DIII-specific IgG antibody titers, purified recombinant DIII-
His proteins of WN and TBE viruses were used as antigens in ELISA. For the 
establishment of this assay, TBE DIII-His and the TBE DIII-specific mab B4 were 
used to compare three different ELISA formats: 
 
1) DIII coated directly to the plate (Fig. 4.15A). 
2) Catching of DIII via the His-tag on Ni2+ coated plates (Fig. 4.15B). 
3) Catching of DIII via the His-tag by anti-His-tag antibody coated plates (Fig. 4.15C). 
 
 
 
Fig. 4.15 Schematic representations of different DIII ELISA formats. 
(A) ELISA format with DIII coated directly to the solid phase of the microtiter plate. 
(B) ELISA format using catching of DIII-His by Ni2+. 
(C) ELISA format using anti-His-tag antibody for catching of DIII-His. 
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As shown in Fig. 4.16, the highest specific reactivities were obtained in the format 
using the anti-His tag mab for catching, followed by direct coating of DIII to the solid 
phase and Ni2+ catching, which was least effective. Therefore, the catching ELISA 
format using the anti-His-tag antibody was further optimized. To investigate the 
specificity of this assay, a WN virus DIII-specific mouse post-immunization serum 
was titrated on recombinant WN virus DIII-His and on plates without antigen. To test 
for possible background reactivities, sera from naïve mice were included in the 
analysis. To compare the sensitivity of the DIII ELISA to that of the standard virion 
ELISA using inactivated whole WN virus as an antigen, the post-immunization serum 
was analyzed in both assays in parallel. As shown in Fig. 4.17, the DIII serum 
showed almost no unspecific reactivity on plates without DIII but strong reactivity with 
DIII and virus, reaching higher titers in the DIII-ELISA format. Background reactivity 
was minimal, as assessed by the use of the negative mouse sera (data not shown). 
This demonstrates the successful establishment of a highly sensitive ELISA for the 
determination of DIII-specific antibody titers. 
 
 
 
Fig. 4.16 Comparison of the reactivity of a DIII-specific mab in three different DIII ELISA 
formats. 
Titration curves of TBE virus DIII specific mab B4 obtained in ELISA with 1, 5 and 10µg/ml 
recombinant TBE virus DIII-His directly coated to the plate (black lines), caught by Ni2+ (blue lines) or 
anti-His-tag antibody (red lines). 
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Fig. 4.17 Reactivity of a DIII specific mouse post-immunization serum in DIII and virion ELISAs. 
Titration curves of a WN virus DIII post-immunization serum on plates without antigen, WN virus DIII-
His or whole inactivated WN virion, indicated in orange, red and black respectively. The error bars 
represent the standard error of the means obtained in three independent determinations. 
 
 
4.2.3.2 Development of an sE ELISA format 
 
For the determination of E protein-specific IgG antibody titers in TBE and WN virus 
sE-specific mouse post-immunization sera, purified recombinant sE-His proteins of 
WN and TBE virus were used as antigens in a catching ELISA format using the anti-
His-tag antibody (compare Fig. 4.15C). Background reactivities were assessed by the 
use of sera from naïve mice. Comparison was also made with the standard virion 
ELISAs using the respective formalin-inactivated whole virus as antigen.  
The sE ELISA formats exhibited almost no unspecific background reactivity as 
assessed by the use of sera from naïve mice (data not shown). As shown in Fig. 
4.18A for the WN and in 4.18B for the TBE virus sE serum, comparable titers were 
reached in the sE and virion ELISAs, but the maximum absorbance was higher in the 
virion ELISA. 
To investigate the suitability of the TBE virus sE ELISA for the detection of broadly 
flavivirus cross-reactive antibodies, an experiment using the cross-reactive mabs 
4G2 and A1 was carried out in comparison to the virion ELISA. The experiment 
revealed that with both mAbs, higher specific reactivities were reached in the sE 
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compared to the virion ELISA (data not shown), suggesting a higher sensitivity of the 
sE ELISA for the detection of cross-reactive abs. As a further analysis of cross-
reactivity, a WN virus-specific mouse post-immunization serum was titrated in the 
TBE virus sE and virion ELISAs. Figure 4.18B shows that - also with the polyclonal 
serum - higher titers were reached in the sE ELISA, confirming the results obtained 
with the cross-reactive mabs. 
These results demonstrate the successful establishment of a sensitive ELISA 
format for the determination of homologous sE-reactive and broadly cross-reactive 
antibody titers. 
 
 
 
Fig. 4.18 Titration curves of sE post-immunization sera in sE and virion ELISAs. 
(A) Titration curves of WN virus sE serum in WN sE (red curve) and WN virion ELISA (green curve).  
(B) Titration curves of TBE virus specific sE post-immunization serum in a TBE virus sE (red curve) 
and virion ELISA (green curve) and of a WN virus-specific serum in a TBE sE (black curve) and TBE 
virion ELISA (blue curve). The error bars represent the standard error of the means obtained in three 
independent determinations. 
 
 
4.2.3.3 Development of antibody depletion assays 
 
To determine the contribution of DIII-specific and broadly cross-reactive antibodies 
to the total neutralizing antibody response in polyclonal mouse post-immunization 
sera, antibody depletion assays were developed, using recombinant WN virus DIII-
His, and heterologous TBE virus sE-His, respectively. The principle of the depletion 
assay is shown in Fig. 4.19. The recombinant His-tagged proteins were bound to 
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Co2+ coated magnetic beads via their His-tags and the loaded beads were 
subsequently incubated with the mouse post-immunization sera. Finally, the beads 
together with the bound antigen-antibody complexes were removed by applying 
magnetic force, leaving the depleted serum in the supernatant, which was further 
analyzed by ELISA and virus neutralization assays. 
 
 
 
Fig. 4.19 Schematic representation of the antibody depletion assay. 
(A) Binding of the His-tagged recombinant protein to the beads. 
(B) Serum depletion with antigen-loaded beads. 
 
 
4.2.3.4 Depletion of DIII-reactive antibodies 
 
For establishing the depletion of DIII-specific antibodies from sera, Co2+ coated 
magnetic beads were incubated with 1, 5 and 10µg of DIII-His. After removal of the 
beads by magnetic force, analysis of the supernatant by SDS-PAGE and 
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densitometric analysis showed that about 40% of the DIII-His used for the binding 
reaction bound to the beads (data not shown). 
For the establishment of depletion of DIII-reactive antibodies from polyclonal 
mouse sera, a WN virus DIII-specific mouse post-immunization serum was incubated 
with WN virus DIII-His loaded beads (1µg of recombinant WN virus DIII-His was used 
for binding to the beads). The supernatant, representing the depleted serum, was 
separated from the beads by magnetic force and further analyzed. To determine the 
efficiency of the serum depletion, the DIII-reactive antibody titers before and after 
depletion were determined by WN virus DIII-His specific ELISA. The ELISA revealed 
that a depletion efficiency of 98% was reached after performing three consecutive 
depletion reactions (Fig. 4.20A). To test whether unspecific binding of antibodies to 
the beads occurred, a WN virus DIII-specific mouse post-immunization serum was 
incubated with blank beads, beads coated with TBE and WN virus DIII-His. The 
depleted sera and the serum before depletion were analyzed by WN virus DIII-
specific ELISA. As shown in Fig. 4.21A, only the WN virus DIII-His coated beads 
were able to remove the WN DIII-reactive antibodies quantitatively. The titration 
curves of sera treated with blank beads and beads coated with TBE virus DIII-His 
were almost identical to the non-depleted control, indicating that no unspecific 
adsorption occurred. 
 
 
Figure 4.20 Analyses of a DIII-specific post-immunization serum after depletion with DIII-His by 
DIII-specific ELISAs. 
(A) Aliquots of the supernatants after each depletion reaction with WN virus DIII-His loaded beads 
were analyzed by DIII-specific ELISA. Titration curves of the depleted sera after the first, second, and 
third round of depletion are indicated by green, blue, and purple lines, respectively.  
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(B) Analysis of a WN virus DIII post-immunization serum before (red curve) and after depletion using 
blank beads (red curve), TBE virus DIII-His (green curve) and WN virus DIII-His loaded beads (blue 
curve) by WN virus DIII-His specific ELISA.  
The cut-offs, indicated by a black horizontal line, were deduced from the reactivity of sera from naïve 
mice. The error bars in panel B represent the standard error of the means obtained in three 
independent determinations. 
 
 
4.2.3.5 Depletion of TBE virus sE-reactive antibodies from TBE and WN virus-
specific sera 
 
For establishing the depletion of TBE virus sE-reactive antibodies from sera, 1, 5, 
10 µg of TBE virus sE-His were incubated with magnetic beads, which were then 
separated from the supernatant by magnetic force. After removal of the beads, the 
supernatant was subjected to analysis by SDS-ELISA to determine the binding 
efficiency. The TBE virus sE-His bound almost quantitatively (>90%) to the beads 
(data not shown). For the depletion of TBE sE reactive antibodies, a TBE virus sE-
specific mouse post-immunization serum was incubated with the loaded beads. To 
assess the depletion efficiency the depleted serum was analyzed by TBE virus sE-
His-specific ELISA. The ELISA revealed that _ after performing three consecutive 
depletion reactions _ more than 95% of the TBE virus sE-reactive antibodies were 
removed (data not shown). To test whether the established conditions are suitable for 
efficient depletion of broadly cross-reactive antibodies, a WN virus-specific mouse 
post-immunization serum and, as a control, the TBE virus sE-specific serum were 
incubated with TBE sE-His coated beads. The depletion efficiency was then 
assessed by TBE virus sE-His specific ELISA. As shown in Fig. 4.21 the reactivity 
was strongly reduced after depletion, showing a reduction in reactivity of more than 
90%.  
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Figure 4.21 Analysis of WN and TBE virus sE post-immunization sera after depletion with TBE 
sE-His by TBE sE-His-specific ELISA 
Analysis of a TBE virus sE (green curves) and a WN virus-specific post-immunization serum, (orange 
curves) before (solid lines) and after depletion (dashed lines) with TBE sE-His, by TBE sE-His-specific 
ELISA. The error bars represent the standard errors of the means obtained in three independent 
determinations. 
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6. Outlook 
 
The key finding of this thesis was that not only the native conformation but also the 
quaternary organisation of the immunogen was a decisive factor for the induction of a 
potent virus neutralizing antibody response. Our findings demonstrate that, due to the 
tight packing of E in the virion, the inactivated virus appears to present primarily 
those antigenic surfaces (on DIII) that are a target of potent neutralizing antibodies. 
In contrast, isolated recombinant antigens (DIII) display antigenic determinants which 
are not exposed on the surface of the viral particle and thus induce antibodies which 
contribute less to neutralization. However, despite its low potency as a priming 
antigen, the isolated DIII was able to strongly booster the most potent neutralizing 
antibodies induced by the inactivated virion.  
It remains a key question whether the findings obtained in the mouse system can 
be generalized to other species, especially humans. In previous studies, a significant 
degree of heterogeneity was observed with respect to fine-specificities of antibody 
responses in mouse, horse and human post-infection sera. Consistent with our work, 
antibodies specific for DIII made up a significant proportion of the IgG response in 
mice, but only a small proportion in humans and horses. In contrast, FP loop-specific 
antibodies were dominant in humans but represented only a minor fraction in mice, 
again consistent with our results. Furthermore, it was shown for both, mice and 
humans that the antibody responses can be subject to strong individual variations. 
Therefore, it will be important to conduct more detailed studies on fine-specificity, 
immunodominance and functional activity, especially in human post-infection/post 
vaccination sera. 
Besides native conformation and quaternary organization of the immunogen, the 
specificity of antibody responses could also be influenced by other factors. For 
instance, it is not clear whether the genetic background of the host can influence fine-
specificity, immunodominance and individual variation of antibody specificity.  
Studies adressing these questions can increase our knowledge of factors that 
control or influence determinants of immunogenicity, fine-specificity and 
immunodominance of antibody responses. A better understanding of these factors 
can improve strategies for the rational design of vaccines with higher immunogenicity 
and protective potency.  
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